nct_id,display_order,candidate_criteria_text
NCT02452008,1,"patients may have had prior therapy including sipuleucel-T, radium-223, abiraterone, ketoconazole, and/or Tak-700"
NCT02452008,1,"however, six cycles of docetaxel are allowed in hormone-sensitive disease)"
NCT02452008,3,Patients may be receiving continuous hormonal ablation with surgical or medical castration with baseline testosterone < 50ng/dL
NCT02452008,15,Aspartate aminotransferase (AST) serum glutamic oxaloacetic transaminase (SGOT)/alanine aminotransferase (ALT) serum glutamate pyruvate transaminase (SGPT) =< 2.5 x ULN (< 5 x ULN if with known liver metastases provided bilirubin is normal)
NCT02452008,16,"Creatinine =< 2.0 x ULN (for patients with > 1.5 x ULN, calculated or measured creatinine clearance must be = 40 mL/minute [Cockcroft-Gault])."
NCT02452008,17,"Men of reproductive potential and those who are surgically sterilized (i.e., postvasectomy) must agree to practice effective barrier contraception that has an expected failure rate of < 1% during and for 6 months after discontinuation of study treatment
* If condoms are used as a barrier contraceptive, a spermicidal agent should be added to ensure that pregnancy does not occur"
NCT02734537,8,Patients with a history of a curatively treated malignancy must be disease-free for at least two years except for carcinoma in situ of cervix and/or non-melanomatous skin cancer; patients must not have received chemotherapy or investigational therapy within two years of surgical resection of the primary tumor
NCT02734537,16,"Women must not be pregnant or breast-feeding due to exposure to cisplatin chemo-and/or radiotherapy; females of childbearing potential must have a blood or urine study within 2 weeks prior to randomization to rule out pregnancy; a female of childbearing potential is any woman, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)"
NCT02734537,17,Women of childbearing potential and sexually active males must be strongly advised to use an accepted and effective method of contraception or to abstain from sexual intercourse for the duration of their participation in the study and until 60 days from the last study treatment
NCT03104491,3,PHASE I: Patients who are between T+40 and T+100 after allogeneic transplantation. Patients must receive their first dose of inotuzumab at or before T+100
NCT03104491,4,"PHASE I: Patients who have/are either:
* Transplanted in hematologic first complete remission with evidence of minimal residual disease within 45 days of allogeneic transplantation
** Pre- or post-transplant minimal residual disease defined by:
*** Any detectable ALL (by flow cytometry, cytogenetics, or polymerase chain reaction [PCR] techniques) as per clinical indication
* In second or third complete remission at the time of allogeneic transplantation
* Treated with reduced intensity regimens or non-myeloablative conditioning regimens
* Lymphoid blast crisis of chronic myelogenous leukemia (CML)
* Are relapsed or refractory to at least 1 line of chemotherapy
* Philadelphia-like ALL"
NCT03104491,5,PHASE I: Patients who have evidence of donor chimerism after allogeneic transplantation
NCT03104491,8,"PHASE I: Subjects must have absolute neutrophil count (ANC) > 1,000/uL for 3 days and platelet transfusion independence as defined as a platelet count > 50,000/uL for 7 days"
NCT03104491,13,PHASE II: Patients who are between T+40 and T+100 after allogeneic transplantation. Patients who received myeloablative conditioning must start between T+70 and T+100. Patients must receive their first dose of inotuzumab at or before T+100
NCT03104491,14,"PHASE II: Patients who have/are either:
* Transplanted in hematologic first complete remission with evidence of minimal residual disease within 45 days of allogeneic transplantation
** Post-Transplant Minimal Residual Disease defined by:
*** Any detectable ALL (by flow cytometry, cytogenetics, or PCR techniques) as per clinical indication
* In second or third complete remission at the time of allogeneic transplantation
* Treated with reduced intensity regimens as defined per institutional standard of practice
* Lymphoid blast crisis of CML
* Are relapsed or refractory to at least 1 line of chemotherapy
* Philadelphia-like ALL"
NCT03104491,15,PHASE II: Patients who have >= 80% donor chimerism after allogeneic transplantation
NCT03104491,19,"PHASE II: Subjects must have ANC > 1,000/uL for 3 days and platelet transfusion independence as defined as a platelet count > 50,000/uL for 7 days"
NCT03161431,14,"Screening laboratory values must meet the following criteria and should be obtained within 14 days prior to first dose: WBC > 3000/µL Neutrophils > 1500/ µL Platelets > 100,000/µL Hemoglobin > 9.0 g/dL (may have been transfused) Creatinine < 1.5 mg/dL AST/ALT < 2.5 X ULN for subject with no liver metastases < 5 X ULN for subjects with liver metastases Bilirubin < 1.5 mg/dL (unless diagnosed with Gilbert's syndrome, who can have total bilirubin < 3.0 mg/dL) INR or PT < 1.5 X ULN unless the subject is receiving anticoagulant therapy aPTT or PTT < 1.5 X ULN unless the subject is receiving anticoagulant therapy"
NCT03161431,21,Women of childbearing potential (WOCBP) must use method(s) of contraception (as will be explained in detail) while on study and for 4 months after the last dose of SX-682 or pembrolizumab. A WOCBP is defined as any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) or is not postmenopausal. Menopause is defined clinically as 12 months of amenorrhea in a woman over age 45 in the absence of other biological or physiological causes.
NCT03161431,23,Women must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 24 hours prior to the start of study drug.
NCT03161431,26,Women who are not of childbearing potential and azoospermic men do not require contraception.
NCT03164460,3,Gross disease apparent on imaging (magnetic resonance imaging [MRI] or computed tomography [CT])
NCT03180268,3,Gross total resection (GTR) will be interpreted as modified Simpson grade 1-3 without gross residual dural-based or extradural tumor. GTR must be confirmed both by modified Simpson grade and by post-operative magnetic resonance imaging (MRI) findings. The modified Simpson grade can be inferred from the operative report (surgeon does not need to explicitly describe the Simpson grade for the purposes of eligibility)
NCT03180268,4,"Step 1 registration must occur within 180 days of the initial surgery; this will provide sufficient time for post-operative imaging confirmation of resection extent after resolution of operative changes. Moreover, it will permit additional surgery if needed to achieve a GTR. Within this 180 day interval, a second surgery is permitted in order to achieve GTR, but even with a second surgery, Step 1 registration must occur within 180 days of the initial resection"
NCT03180268,11,"History/physical examination, including neurologic examination within 60 days prior to step 2 registration"
NCT03180268,13,"If the patient is a woman is of childbearing potential, a serum pregnancy test, obtained within 14 days prior to step 2 registration, must be negative, and, if randomized to receive radiation therapy, the woman must agree to use contraception"
NCT03186898,11,Albumin >= 2.5 g/dl
NCT03186898,12,Creatinine < 2 mg/dl
NCT03186898,13,"Prior chemotherapy, targeted biological therapy (e.g. sorafenib), surgery, transarterial chemoembolization (TACE), ablation for present disease is acceptable"
NCT03277638,4,History/physical examination within 7 days prior to registration
NCT03277638,9,"Creatine =< 1.7 x upper limit of normal (ULN) OR measure or calculated creatinine clearance (glomerular filtration rate [GFR] can also be used in place of creatinine or creatinine clearance [CrCl]) >= 70.0 mL/min for subject with creatinine levels > 1.5 X institutional ULN (within 7 days of registration)
* Creatinine clearance should be calculated per institutional standard"
NCT03277638,15,The treating physician expects that the patient will not require more than physiologic replacement dose of steroids defined as4 mg of dexamethasone per day or its equivalent.
NCT03277638,20,Male subjects must agree to use an adequate method of contraception for the duration of the study through 120 days after the last dose of study therapy
NCT03277638,23,It is permissible to plan combined LITT followed by immediate post LITT tumor debulking in the same operation for tumors at the discretion of the surgeon with goal of avoiding post-LITT swelling and ICP issues as long as >= 1 cm^3 of tumor is left as “index lesion”
NCT03277638,24,Active tumor must be Unifocal & Unilateral. Two enhancing nodules within the same fluid attenuated inversion recovery (FLAIR) hyperintense region are still eligible; 1-2 secondary enhancing or non-enhancing lesions may be present as long as they have been radiologically stable for >= 3 mo)
NCT03277638,45,"Age >= 18 for two reasons:
*
*No dosing or adverse event data are currently available on the use of pembrolizumab in subjects’ =< 18 years of age. 
*GBM and GS in children have much better prognosis than adults, children, are excluded from this study."
NCT03422198,1,"Histologically confirmed endometrial carcinoma: endometrioid type, serous, and clear cell to include tumors originating in the cervix, but are primarily located in the uterus, and for whom vaginal cuff brachytherapy is indicated; carcinosarcoma and other sarcomas are permitted; Federation of Gynecology and Obstetrics (FIGO) stage I and stage II, with one of the following combinations of stage and grade:
* Stage IA, grade 1 with lymphatic invasion (LVSI), 2, 3
* Stage IB, grades 1-3
* Stage II, grades 1-3
* Stage IIIA, grades 1-3, not receiving external beam radiation therapy (EBRT) as part of adjuvant therapy"
NCT03465592,6,Concomitant radiation therapy can be administered in the setting of this trial.
NCT03465592,7,"Subjects must consent to allow for a baseline tumor biopsy. If a biopsy is not feasible, then archival tumor material must be made available. Tumor biopsies to be taken (if a subject’s tumor is thought to be reasonably safe and easy to biopsy) at baseline (any time prior to the first dose after eligibility is met) and at cycle 2 (4-6 cores per time point) or when lesions are visualized on physical examination or imaging studies in the case of no identifiable masses at cycle 2. Additional optional biopsies may be obtained later in the course of study treatment. Detailed instructions for tissue collection, processing and shipment are provided. The proposed investigation is considered a non-significant risk (NSR). A significant risk procedure is generally considered to be one for which the procedure-associated absolute risk of mortality or major morbidity, in the patient’s clinical setting and at the institution completing the procedure, is 2% or higher. Diagnostic Tissue Samples Tissue, fluid, or blood may be collected from standard of care procedures used to treat or diagnose immune related toxicities/graft versus host disease (GVHD)."
NCT03465592,11,"Creatinine clearance or radioisotope glomerular filtration rate (GFR) >= 70 ml/min/1.73 m^2 or a serum creatinine based on age/gender as follows:
* Age 1 to < 2 years, Male: 0.6 and Female: 0.6 (maximum serum creatinine [mg/dl])
* Age 2 to < 6 years, Male: 0.8 and Female: 0.8 (maximum serum creatinine [mg/dl])
* Age 6 to < 10 years, Male: 1 and Female: 1 (maximum serum creatinine [mg/dl])
* Age 10 to < 13 years, Male: 1.2 and Female: 1.2 (maximum serum creatinine [mg/dl])
* Age 13 to < 16 years, Male: 1.5 and Female: 1.4 (maximum serum creatinine [mg/dl])
* Age >= 16 years, Male: 1.7 and Female: 1.4 (maximum serum creatinine [mg/dl])"
NCT03465592,12,Bilirubin (sum of conjugated + unconjugated) =< 1.5 x upper limit of normal (ULN) for age
NCT03465592,13,"Serum glutamic pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) =< 110 U/L. For the purpose of this study, the ULN for SGPT is 45 U/L"
NCT03488693,3,Post-mastectomy positive margins for invasive breast cancer and/or DCIS is not allowed
NCT03488693,8,"Patients with nodal macrometastases (> 2 mm) treated by sentinel lymph node biopsy (SLNB) alone must have only 1-2 positive axillary nodes (macrometastases, > 2 mm)
* Note patients with additional nodal micrometastases (> 0.2-2mm) or isolated tumour cells (=< 0.2 mm) are eligible"
NCT03488693,10,"Patients must have an Oncotype DX recurrence score =< 25 obtained from testing of breast tumor tissue from a core biopsy or from the surgical specimen
* If the patient does not already have Oncotype DX recurrence score, specimen (unstained blocks or slides) must be sent to the Exact Sciences centralized laboratory in Redwood City, California
* Oncotype DX testing must be performed on a core biopsy PRIOR to commencement of neoadjuvant endocrine therapy"
NCT03488693,13,"Patients must have had endocrine therapy initiated or planned for >= 5 years; premenopausal women will receive ovarian ablation plus aromatase inhibitor therapy or tamoxifen if adjuvant chemotherapy was not administered; for all patients, endocrine therapy can be given concurrently or following RT"
NCT03488693,14,Patients may or may not have had adjuvant chemotherapy
NCT03488693,15,"RT must commence within 16 weeks of definitive surgery if the patient is not treated with chemotherapy; if adjuvant chemotherapy is given, RT must begin within 12 weeks after the last dose; (Note: adjuvant chemotherapy may be ongoing at the time of randomization)
* Note: Definitive surgery is defined as the last breast cancer-related surgery"
NCT03488693,22,"Women of childbearing potential must have agreed to use an effective contraceptive method; a woman is considered to be of ""childbearing potential"" if she has had menses at any time in the preceding 12 consecutive months; in addition to routine contraceptive methods, ""effective contraception"" also includes heterosexual celibacy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy, bilateral oophorectomy or bilateral tubal ligation, or vasectomy/vasectomized partner; however, if at any point a previously celibate patient chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol, she is responsible for beginning contraceptive measures
* Women of childbearing potential will have a pregnancy test to determine eligibility as part of the Pre-Study Evaluation; this may include an ultrasound to rule-out pregnancy if a false-positive is suspected; for example, when beta-human chorionic gonadotropin is high and partner is vasectomized, it may be associated with tumor production of human chorionic gonadotropin (hCG), as seen with some cancers; patient will be considered eligible if an ultrasound is negative for pregnancy"
NCT03556228,0,"Histologically or cytologically confirmed diagnosis of any type of solid tumor malignancy or lymphoma that is not responsive to standard therapies or had progressed following standard therapy and for which there is no approved or curative therapy. Additionally, patients must not be candidates for or have exhausted regimens known to provide clinical benefit, including hematopoietic stem cell transplantation in lymphoma patients if they are deemed transplant eligible."
NCT03556228,5,"Subjects must have a tumor: (i). with TrkA protein overexpression (TrkA+) in the validated TrkA IHC assay, OR (ii). with documented NTRK1 gene fusion (NTRK1+) including a tumor which has progressed due to NTRK1 mutation after treatment of a pan-Trk inhibitor (e.g. larotrectinib or entrectinib)"
NCT03556228,13,"Creatinine ≤1.2xULN for age, weight"
NCT03602157,4,"* If the subject has Hodgkin lymphoma, the subject must have either failed autologous transplant or must not be eligible for autologous transplant.
* If the subject has grey zone lymphoma, the subject must have failed an anthracycline containing regimen unless the subject was not previously a candidate for anthracycline.
* Subjects relapsed after autologous or allogeneic stem cell transplant are eligible for this study."
NCT03602157,11,PRIOR TO CELL PROCUREMENT: Subjects must not be using systemic corticosteroids at doses >= 10mg prednisone daily or its equivalent; those receiving < 10mg daily may be enrolled at discretion of the investigator.
NCT03602157,14,PRIOR TO CELL PROCUREMENT: Subjects must not have a history of intolerance to fludarabine. Subjects with an intolerance to bendamustine may be allowed to enroll at the discretion of the clinical investigator if he/she thinks that the subject is a candidate for lymphodepletion with cyclophosphamide and fludarabine.
NCT03602157,17,PRIOR TO PROCUREMENT: Bilirubin =< 1.5 times the upper limit of normal (ULN). Subjects with Gilbert's syndrome may be enrolled despite a total bilirubin level > 1.5 mg/dL if their conjugated bilirubin is < 1.5 x ULN).
NCT03602157,19,PRIOR TO PROCUREMENT: Serum creatinine =< 1.5 times ULN.
NCT03602157,21,PRIOR TO PROCUREMENT: Pulse oximetry of > 90% on room air.
NCT03602157,23,"PRIOR TO CELL PROCUREMENT: Negative serum pregnancy test within 72 hours prior to procurement or documentation that the subject is post-menopausal. Post-menopausal status must be confirmed with documentation of absence of menses for > 1 year, or documentation of surgical menopause involving bilateral oophorectomy."
NCT03602157,27,PRIOR TO LYMPHODEPLETION: Presence of active disease by imaging and/or cutaneous involvement. Imaging must be performed within 7 days prior to lymphodepletion to confirm presence of active disease. Subjects who have received bridging chemotherapy must have imaging performed at least 3 weeks after most recent therapy (imaging does not need to be repeated if it is within 7 days prior to lymphodepletion).
NCT03602157,28,"PRIOR TO LYMPHODEPLETION: Adequate bone marrow function (absolute neutrophil count (ANC) > 1000 cells/mm^3 and platelets > 50,000/mm^3). Subjects cannot have received platelet transfusion within 7 days of lymphodepletion."
NCT03602157,29,PRIOR TO LYMPHODEPLETION: Bilirubin =< 1.5 times the upper limit of normal (ULN). Subjects with Gilbert's syndrome may be treated despite a total bilirubin level > 1.5 mg/dL if their conjugated bilirubin is < 1.5 x ULN).
NCT03602157,31,PRIOR TO LYMPHODEPLETION: Serum creatinine =< 2 times ULN.
NCT03602157,33,PRIOR TO LYMPHODEPLETION: Pulse oximetry of > 90% on room air.
NCT03602157,34,PRIOR TO LYMPHODEPLETION: Negative serum pregnancy test within 72 hours prior to lymphodepletion or documentation that the subject is post-menopausal. Post-menopausal status must be confirmed with documentation of absence of menses for > 1 year or documentation of surgical menopause involving bilateral oophorectomy.
NCT03602157,38,PRIOR TO LYMPHODEPLETION: Has not received chemotherapy or radiation therapy within the previous 3 weeks prior to lymphodepletion.
NCT03602157,39,"PRIOR TO LYMPHODEPLETION: Subjects cannot be on strong inhibitors of CYP1A2 (e.g., fluvoxamine, ciprofloxacin) as these may increase plasma concentrations of bendamustine, and decrease plasma concentrations of its metabolites. (This applies to subjects who receive bendamustine for lymphodepletion [required] up through 72 hours after the last dose of bendamustine)."
NCT03602157,45,PRIOR TO LYMPHODEPLETION: Subjects must not be using systemic corticosteroids at doses >= 10mg prednisone daily or its equivalent; those receiving < 10mg daily may be treated at discretion of the investigator.
NCT03602157,47,PRIOR TO CELL INFUSION AFTER LYMPHODEPLETION: Bilirubin =< 2 times the upper limit of normal (ULN) unless attributed to Gilbert’s syndrome.
NCT03602157,50,PRIOR TO CELL INFUSION AFTER LYMPHODEPLETION: Serum creatinine =< 3 times ULN.
NCT03602157,51,PRIOR TO CELL INFUSION AFTER LYMPHODEPLETION: Pulse oximetry of > 90% on room air.
NCT03602157,58,PRIOR TO LYMPHODEPLETION FOR OPTIONAL REINFUSION: Must not have current use of systemic corticosteroids at doses >= 10 mg prednisone daily or its equivalent; those receiving < 10 mg daily may be enrolled at discretion of the Investigator.
NCT03602157,59,PRIOR TO LYMPHODEPLETION FOR OPTIONAL REINFUSION: ANC > 1000 cells/mm^3. Subjects cannot have received platelet transfusion within 7 days of lymphodepletion. Note: Subjects may receive a second infusion without prior lymphodepletion or with a 25-50% dose reduction in bendamustine if they meet all other eligibility criteria at the time of infusion.
NCT03602157,60,"PRIOR TO LYMPHODEPLETION FOR OPTIONAL REINFUSION: Platelets > 50,000/mm^3. Subjects cannot have received platelet transfusion within 7 days of lymphodepletion. Note: Subjects may receive a second infusion without prior lymphodepletion or with a 25-50% dose reduction in bendamustine if they meet all other eligibility criteria at the time of infusion."
NCT03602157,61,PRIOR TO LYMPHODEPLETION FOR OPTIONAL REINFUSION: Bilirubin =< 1.5 times the upper limit of normal (ULN). Subjects with Gilbert's syndrome may be enrolled despite a total bilirubin level > 1.5 mg/dL if their conjugated bilirubin is < 1.5 x ULN)
NCT03602157,63,PRIOR TO LYMPHODEPLETION FOR OPTIONAL REINFUSION: Serum creatinine =< 2 times ULN.
NCT03602157,65,PRIOR TO LYMPHODEPLETION FOR OPTIONAL REINFUSION: Pulse oximetry of > 90% on room air.
NCT03602157,66,PRIOR TO LYMPHODEPLETION FOR OPTIONAL REINFUSION: Negative serum pregnancy test within 72 hours prior to lymphodepletion or documentation that the subject is post-menopausal. Post-menopausal status must be confirmed with documentation of absence of menses for > 1 year or documentation of surgical menopause involving bilateral oophorectomy.
NCT03602157,67,"PRIOR TO LYMPHODEPLETION FOR OPTIONAL REINFUSION: Subjects cannot be on strong inhibitors of CYP1A2 (e.g., fluvoxamine, ciprofloxacin) as these may increase plasma concentrations of bendamustine, and decrease plasma concentrations of its metabolites."
NCT03602157,71,PRIOR TO INFUSION OF OPTIONAL REINFUSION: Bilirubin =< 2 times the upper limit of normal (ULN) unless attributed to Gilbert’s syndrome.
NCT03602157,74,PRIOR TO INFUSION OF OPTIONAL REINFUSION: Serum Creatinine =< 3 times ULN.
NCT03602157,75,PRIOR TO INFUSION OF OPTIONAL REINFUSION: Pulse oximetry of > 90% on room air.
NCT03618550,1,Histologic diagnosis of classical Hodgkin’s lymphoma. Primary refractory or relapsed disease proven by biopsy at enrolling institution.
NCT03618550,4,Eligible for high dose therapy (HDT)/ASCT.
NCT03618550,5,Achieved complete response (Deauville 3 or better) following 2 cycles of pembro-GVD.
NCT03618550,13,Serum creatinine =< 1.5 X upper limit of normal (ULN) OR measured or calculated creatinine clearance (CrCl) (glomerular filtration rate [GFR] can also be used in place of creatinine or CrCl) >= 60 mL/min for subject with creatinine levels > 1.5 X institutional ULN.
NCT03618550,15,Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SPGT]) =< 2.5 X ULN OR =< 5 X ULN for subjects with liver metastases.
NCT03618550,16,Hemoglobin-adjusted diffusing capacity for carbon monoxide >= 50%. (If unadjusted carbon monoxide diffusing capability test [DLCO] is >= 50% then there is no need to calculate adjusted.)
NCT03618550,18,"Female subject of childbearing potential should have a negative urine or serum pregnancy within 2 weeks prior to receiving the first dose of study medication. On the day of planned treatment, if a blood pregnancy test has not been performed within the two week window, a stat pregnancy test (urine or blood) should be performed and the results reviewed before treatment is begun"
NCT03618550,19,Female subjects of childbearing potential must be willing to use an adequate method of contraception.
NCT03618550,20,Male subjects of childbearing potential must agree to use an adequate method of contraception.
NCT03618550,21,"HIV-infected participants must have well-controlled HIV on antiretroviral therapy (ART), defined as:
* Participants on ART must have a CD4+ T-cell count ≥ 350 cells/mm^3 at the time of screening.
* Participants on ART must have achieved and maintained virologic suppression defined as confirmed HIV ribonucleic acid (RNA) level below 50 copies/mL or the lower limit of quantification (LLOQ) (below the limit of detection) using the locally available assay at the time of screening and for at least 12 weeks before screening.
* It is advised that participants must not have had any AIDS-defining opportunistic infections within the past 12 months.
* Participants on ART must have been on a stable regimen, without changes in drugs or dose modification, for at least 4 weeks before study entry (day 1) and agree to continue ART throughout the study."
NCT03618550,22,Participants who have AEs due to previous anticancer therapies must have recovered to ≤ grade 1 or baseline. Participants with endocrine-related AEs who are adequately treated with hormone replacement or participants who have ≤ grade 2 neuropathy are eligible.
NCT03618550,23,"Archival tumor tissue sample or newly obtained (core, incisional or excisional) biopsy of a tumor lesion not previously irradiated has been provided. Formalin- fixed, paraffin embedded (FFPE) tissue blocks are preferred to slides. Newly obtained biopsies are preferred to archived tissue."
NCT03708224,10,"Serum creatinine =< 1.5 x upper limit of normal (ULN) OR calculated creatinine clearance >= 50 mL/min creatinine clearance by Cockcroft-Gault formula for participants in whom, in the investigator‘s judgment, serum creatinine levels do not adequately reflect renal function (performed within 14 days of treatment initiation)
* Creatinine clearance should be calculated by Cockcroft-Gault formula or per institutional standard"
NCT03708224,13,Albumin >= 2.5 mg/dL (performed within 14 days of treatment initiation)
NCT03708224,17,"Female subjects of childbearing potential must be willing to use an adequate method of contraception, for the course of the study through 5 months after the last dose of study medication"
NCT03708224,18,"Male subjects must agree to use an adequate method of contraception and refrain from donating sperm, starting with the first dose of study therapy through 5 months after the last dose of study therapy.
* Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject"
NCT03710421,1,"Documented informed Screening and Leukapheresis consent of the participant and/or legally authorized representative.
* Assent, when appropriate, will be obtained per institutional guidelines."
NCT03710421,2,"Agreement to allow the use of archival tissue from diagnostic tumor biopsies 
* If unavailable, exceptions may be granted with study primary investigator approval
Note: For research participants who do not speak English, a short form consent may be used with a COH certified interpreter/translator to proceed with screening and leukapheresis, while the request for a translated full consent is processed."
NCT03710421,9,"Participant must have relapsed or refractory disease after all 3 prior treatment regimens with the following requirements:
* Participant must have received prior treatment with an immunomodulatory agent.
* Participant must have received prior treatment with a proteasome inhibitor.
* Participant must have received prior treatment with an anti‐CD38 antibody.
* Participants must be refractory to last line of therapy prior to study enrollment (refractory myeloma is defined as disease that is nonresponsive, progression on treatment, or shows progression within 60 days after the last prior line of therapy).
* Participants who were not candidates to receive one or more of the above treatments are eligible; however, the reason must be clearly documented in the case report form.
NCT03710421,11,Total serum bilirubin =< 2.0 mg/dL.
NCT03710421,15,"Serum creatinine =< 2.5 x ULN or estimated creatinine clearance of >= 40 mL/min per the Cockcroft‐Gault formula, and the participant is not on hemodialysis."
NCT03710421,20,Oxygen (O2) saturation >= 92%.
NCT03728335,7,GvHD prophylaxis: sirolimus + tacrolimus or tacrolimus + methotrexate or investigator choice
NCT03728335,17,Creatinine clearance of >= 40/min/1.73 m^2 for participants with creatinine levels above institutional normal per 24 hour urine test or the Cockcroft‐Gault formula (performed within 28 days prior to day 1 of protocol therapy unless otherwise stated)
NCT03728335,19,"Seronegative for human immunodeficiency virus (HIV) antigen/antibody (Ag/Ab) combo, hepatitis C virus (HCV), active hepatitis B virus (HBV) (surface antigen negative), and syphilis (rapid plasma reagin [RPR])
* If positive, hepatitis C ribonucleic acid (RNA) quantitation must be performed"
NCT03734692,2,"Patients must have first or second peritoneal recurrence of epithelial adenocarcinoma or carcinosarcoma of ovarian, tubal or peritoneal origin:
* Histologic documentation of the original primary tumor is required via the pathology report.
* Original tumor blocks from the primary diagnosis will be requested by our study pathologist at Magee-Women’s Hospital of University of Pittsburgh Medical Center (UPMC) Cancer Centers. Original tumor blocks may be reviewed after registration (informed consent and enrollment)."
NCT03734692,4,"Patients must be platinum-sensitive, defined as having a progression free interval (PFI) of more than 6 months (180 days) from any platinum therapy. Patients are allowed to have had other lines of therapy since last platinum if PFI after platinum therapy meets platinum sensitive criteria."
NCT03734692,5,"Patients must have measurable disease in the peritoneal cavity, measurable per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria:
* A mass with a length of 1.0 cm or greater and/or
* A lymph node with a length of 1.5 cm or greater in the shortest axis."
NCT03734692,6,"Patients must be a reasonable candidate for laparoscopy and IP platinum regimen with no prior evidence of clinically significant intra-abdominal adhesions, persistent abdominal wall infections, renal toxicity or bowel obstruction."
NCT03734692,14,Creatinine =< 1.5 upper limit of normal (ULN) OR measured or calculated creatinine clearance (glomerular filtration rate [GFR] can also be used in place of creatinine or creatinine clearance [CrCl]) >= 30 mL/min with creatinine levels > 1.5 institutional ULN (collected within 14 days prior to the start of study treatment).
NCT03761108,1,Confirmed diagnosis of active Multiple Myeloma (MM) by International Myeloma Working Group (IMWG) diagnostic criteria
NCT03761108,3,"Phase 1, Part 1 (Dose Escalation): Patients with MM who have exhausted all therapeutic options that are expected to provide meaningful clinical benefit, either through disease relapse, treatment refractory disease or intolerance of the therapy and including either: a. Progression on or after at least 3 lines of therapy, or intolerance of therapy, including a proteasome inhibitor, an Immunomodulatory agent (IMiD), and an anti-CD38 antibody, OR b. Progression on or after an anti-CD38 antibody and have disease that is ""double refractory"" to a proteasome inhibitor and an IMiD, or intolerance of therapy. The anti-CD38 antibody may have been administered alone or in combination with another agent such as a proteasome inhibitor (PI). Refractory disease is defined as lack of response or relapse within 60 days of last treatment."
NCT03761108,4,"Phase 1, Part 2 (SC Administration): Patients with MM whose disease meets the following criteria: a. Progression on or after at least 3 prior lines of therapy including a(n) PI, IMiD, and anti-CD38 antibody, OR b. Patients must be triple-refractory, defined as being refractory to prior treatment with at least 1 anti-CD38 antibody, a proteasome inhibitor, and an IMiD."
NCT03761108,5,"Phase 2 (Cohorts 1 and 2): Patients with MM whose disease meets the following criteria: a. Progression on or after at least 3 prior lines of therapy including a(n) PI, IMiD, and anti-CD38 antibody, OR b. Patients must be triple- refractory, defined as being refractory* to prior treatment with at least 1 PI, 1 IMiD, and an anti-CD38 antibody."
NCT03761108,7,"Progression on or after at least 3 prior lines of therapy including a(n) PI, IMiD, and anti-CD38 antibody, OR"
NCT03761108,8,"Patients must be triple- refractory, defined as being refractory* to prior treatment with at least 1 PI, 1 IMiD, and an anti-CD38 antibody."
NCT03761108,9,"Refractory disease is defined as progression during treatment or within 60 days after completion of therapy, or <25% response to therapy. AND, for ALL patients, if they have relapsed after a BCMA-directed CAR-T cellular therapy then: • Treatment with a CAR-T must have been associated with a response of PR or better, and • If CAR-T cellular therapy was the most recent prior therapy, excluding corticosteroids, then treatment must have been a minimum of 60 days prior to treatment with REGN5458. Key"
NCT03785288,2,Surgery consisted of total abdominal or laparoscopic hysterectomy and bilateral salpingo oophorectomy (TH-BSO) with or without lymph node dissection
NCT03819296,8,"PROJECT 2: ICPI-related colitis and/or diarrhea of grade >= 2 as GI toxicity (initial episode or recurrence) receiving standard treatment of immunosuppressive agents (steroid, infliximab, vedolizumab, or ustekinumab) any time during the colitis disease course until sustained resolution of GI toxicity, or one- year time point after enrollment"
NCT03819296,10,"PROJECT 3: ICPI-related colitis and/or diarrhea of grade >= 2 within 45 days prior to FMT with ANY of the following characteristics: 
* refractory to treatment of steroid and two doses of non-steroidal immunosuppressants e.g. infliximab and/or vedolizumab or ustekinumab
* contraindication for immunosuppressive treatment
* recurrence after successful initial treatment
* recurrent symptoms once steroid is tapered down/off or diarrhea/colitis symptoms are steroid dependent, or
* patients with a history of refractory ICPI-related colitis and/or diarrhea to medical treatment, even if they have improved symptoms from supportive care within 45 days prior to FMT"
NCT03900793,4,"Histologically confirmed osteosarcoma (at either original diagnosis or relapse) that has either recurred or progressed after at least one prior systemic therapy and for which no curative therapy exists.
* Patients with surface or periosteal osteosarcoma are not eligible
* Patients with active central nervous system (CNS) metastasis are not eligible. Previously treated CNS metastases which occurred 3 months or more prior, without evidence of active recurrence, are acceptable"
NCT03900793,5,DOSE ESCALATION (PART A): Patients must have measurable or evaluable disease
NCT03900793,9,Cytotoxic chemotherapy or other anti-cancer agents known to be myelosuppressive. At least 21 days after the last dose of cytotoxic or myelosuppressive chemotherapy (42 days if prior nitrosourea)
NCT03900793,11,"Antibodies: >= 21 days must have elapsed from infusion of last dose of antibody, and toxicity related to prior antibody therapy must be recovered to grade =< 1"
NCT03900793,12,Corticosteroids: >= 14 days must have elapsed since last dose of corticosteroid
NCT03900793,13,"Hematopoietic growth factors: >= 14 days after the last dose of a long- acting growth factor (e.g., pegfilgrastim) or 7 days for short-acting growth factor"
NCT03900793,16,"Cellular therapy: >= 42 days after the completion of any type of cellular therapy (e.g., modified T cells, NK cells, dendritic cells, etc.)"
NCT03900793,17,"Radiation therapy (XRT)/External beam irradiation including protons: >= 14 days after local XRT; >= 150 days after total body irradiation (TBI), craniospinal XRT or if radiation to >= 50% of the pelvis; >= 42 days if other substantial bone marrow radiation
* NOTE: Patients with history of cardiac irradiation with mean cardiac dose > 15 Gy are not eligible (see exclusion criteria)"
NCT03900793,21,"Creatinine clearance or radioisotope glomerular filtration rate (GFR) >= 70 mL/min/1.73 m^2 OR a serum creatinine based on age/gender as follows:
* Age 2 to < 6 years, maximum serum creatinine (mg/dL): 0.8 (male); 0.8 (female)
* Age 6 to < 10 years, maximum serum creatinine (mg/dL): 1 (male); 1 (female)
* Age 10 to < 13 years, maximum serum creatinine (mg/dL): 1.2 (male); 1.2 (female)
* Age 13 to < 16 years, maximum serum creatinine (mg/dL): 1.5 (male); 1.4 (female)
* Age >= 16 years, maximum serum creatinine (mg/dL): 1.7 (male); 1.4 (female)"
NCT03900793,25,Patients with >= trace protein on urinalysis at screening will be allowed to enroll in the study at investigator discretion. A baseline urine protein creatinine ratio (UPC) should be obtained for patients with >= trace protein on urinalysis for consideration regarding dose modification requirements
NCT03987386,2,"Patient has diagnosis of pathologically confirmed prostate cancer, treated with radical prostatectomy. Any type of radical prostatectomy will be permitted, including retropubic, perineal, laparoscopic, or robotically assisted"
NCT03987386,4,"For patients radiated in the post-operative salvage setting: pathology can demonstrate any of the following features but not required, positive margin, extracapsular extension, or seminal vesicle involvement with detectable prostate-specific antigen (PSA) of >= 0.1. PSA >= 0.1 after radical prostatectomy: most recent PSA value within 12 months of registration and prior to initiating any androgen deprivation therapy (ADT)"
NCT04038619,5,"Patients with a history of immunosuppressant (infliximab, vedolizumab etc) use before FMT can be allowed if last dose was administered >= 3 months prior to FMT treatment when used for the treatment of conditions other than for ICI- induced GI toxicities (e.g., infliximab is used in the treatment of Crohn’s disease, rheumatoid arthritis, plaque psoriasis, and vedolizumab is used in treating ulcerative colitis)"
NCT04090567,4,Hemoglobin (Hgb) >= 10.0 g/dL (measured within 28 days [baseline screening]) with no blood transfusion in the past 28 days prior to the administration
NCT04090567,11,"Negative urine or serum pregnancy test within 28 days of study treatment and confirmed prior to treatment on cycle 1 day 1 and during the study for child bearing potential women 
* Female subjects must either be of non-reproductive potential (i.e., post-menopausal by history: >= 60 years old and no menses for >= 1 year without an alternative medical cause; OR history of hysterectomy, OR history of bilateral tubal ligation, OR history of bilateral oophorectomy) or must have a negative serum pregnancy test upon study entry and be using highly effective contraception (that is, methods with a failure rate of less than 1% per year) for both male and female subjects if the risk of conception exists (Note: The effects of the trial treatment on the developing human fetus are unknown; thus, women of childbearing potential and men must agree to use highly effective contraception, defined in E or as stipulated in national or local guidelines). Highly effective contraception must be used 30 days prior to first trial treatment administration, for the duration of trial treatment, and at least for 1 month after stopping trial treatment"
NCT04090567,13,"Patient has measurable disease, per Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1. At least one lesion, not previously irradiated, that can be accurately measured at baseline as >= 10 mm in the longest diameter (except lymph nodes which must have short axis >= 15 mm) with computed tomography (CT) or magnetic resonance imaging (MRI)"
NCT04090567,17,Able to swallow and retain oral medications and without gastrointestinal (GI) illnesses that would preclude absorption of olaparib or ceralasertib
NCT04134260,1,"Pathologically (histologically) proven diagnosis of prostate adenocarcinoma. Any type of radical prostatectomy is permitted, including retropubic, perineal, laparoscopic or robotically assisted"
NCT04134260,3,"Appropriate stage for study entry based on fluciclovine F-18 PET scan (FACBC, Axumin) F-18 prostate-specific membrane antigen (PSMA) PET (PyLarify) scan, Gallium-68 PSMA PET scan, flotufolastat F-18 PSMA PET scan (Posluma), or C-11 or F-18 Choline PET within 90 days prior to registration that is negative for distant metastatic (M1a, M1b, M1c) disease. For patients with PSA < 0.20 ng/mL at time of registration, PET scan is recommended but not required"
NCT04134260,4,"Pathologically node positive disease with nodal involvement only in the pelvis in the prostatectomy specimen or nodal disease on imaging at time of recurrence (including external iliacs, internal iliacs, and/or obturator nodes); peri-prostatic and peri-rectal nodes can also be considered regional lymphadenopathy and are allowed"
NCT04134260,5,History/physical examination within 90 days prior to registration
NCT04134260,8,Detectable PSA after radical prostatectomy. Detectable PSA is defined as serum PSA > 0 ng/mL at least 30 days after prostatectomy
NCT04134260,9,Patients who have already started on post-prostatectomy GnRH agonist/antagonist for =< 180 days prior to registration are eligible (Note: patients who started on an oral antiandrogen are eligible if started =< 180 days and stopped prior to registration)
NCT04134260,12,Serum potassium >= 3.5 mmol/L within 90 days prior to registration
NCT04174352,1,"Patients must have histologically confirmed breast cancer that is metastatic or unresectable with the following:
* Estrogen receptor expression by immunohistochemistry >= 10%
* ESR1 mutation identified using a Clinical Laboratory Improvement Act (CLIA) certified assay via tumor biopsy tissue or circulating free deoxyribonucleic acid (DNA) (cfDNA)
* HER2 negative"
NCT04174352,2,Patients must have measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 or evaluable bone-only disease with at least one lesion measuring 10 mm or greater in size. (Patients with both bone and non-bone disease are eligible. One disease site must meet either the measurable or evaluable criteria outlined). Patients with liver-only disease are not eligible due to the inherent hepatic uptake related to the radiopharmaceutical’s hepatobiliary route of elimination
NCT04174352,3,Patients must have received at least 1 prior line of endocrine therapy in the metastatic setting or have had progression within 12 months of adjuvant endocrine therapy. Prior tamoxifen is allowed in any setting. Prior CDK4/6 in the metastatic setting per NCCN guidelines is allowed
NCT04174352,9,"Patients with central nervous system (CNS) metastases must be stable after therapy for CNS metastases (such as surgery, radiation, or stereotactic radiosurgery) for at least 1 month"
NCT04174352,15,Creatinine =< 1.5 x ULN or creatinine clearance >= 50 mL/min
NCT04175431,2,Patient must previously have undergone radical prostatectomy
NCT04175431,3,Patient must previously have undergone either adjuvant or salvage radiation therapy to the prostatic fossa +/- whole pelvis
NCT04175431,6,Patient must have no previous evidence of radiographically detectable metastatic prostate cancer by conventional CT and bone scan imaging
NCT04175431,12,Potassium >= 3.5
NCT04175431,13,Serum bilirubin =< 1.5 X upper limit of normal (ULN) or =< 3 X ULN for patients with documented Gilbert’s syndrome
NCT04189757,1,"Confirmed diagnosis of mantle cell lymphoma with CD20 positivity and chromosome translocation t(11;14), (q13;q32) and/or overexpress cyclin D1 in tissue biopsy. Patients who have had a bone marrow aspirate (BMA)/bone marrow (BM) biopsy (Bx) and/or gastrointestinal (GI) endoscopy and biopsy and/or tissue biopsy performed and confirming MCL at MD Anderson Cancer Center (MDACC) within 42 days prior to screening do not need to repeat the invasive procedure at screening"
NCT04189757,2,Include patients who require treatment (versus watch/wait) or patients who are in complete remission on ibrutinib/BTK inhibitor maintenance therapy or those who require maintenance therapy and had discontinued ibrutinib/BTK inhibitor earlier for reasons other than progression/relapse
NCT04189757,3,Prior treatment with ibrutinib discontinued for reasons other than progression
NCT04189757,4,Patients who were on ibrutinib-rituximab maintenance and who develop ibrutinib associated toxicities/ibrutinib associated reasons for discontinuation (other than disease progression) are allowed to continue rituximab and SWITCH to acalabrutinib
NCT04189757,5,"Intolerance is defined as unacceptable or intolerable toxicity, [where, in the opinion of the investigator, treatment should be discontinued in spite of optimal supportive care (including management according to ibrutinib basic prescribing information)] defined as one of the following:
* 2 or more grade >= 2 non-hematological toxicities; OR
* 1 or more grade 3 >= 3 non-hematological toxicity; OR
* 1 or more grade 3 neutropenia with infection or fever; OR,
* Grade 4 hematologic toxicity which persists to the point that the investigator chose to stop therapy due to toxicity NOT progression
** Toxicity must have resolved to =< grade 1 prior to acalabrutinib dosing"
NCT04189757,8,Patients who are in complete response or partial response while taking another BTK inhibitor such as ibrutinib but had to discontinue due to intolerance are eligible even in the absence of measurable disease to maintain the achieved response
NCT04189757,9,"Bi-dimensional measurable disease using the Cheson 2014 criteria or Lugano criteria (measurable disease by positron emission tomography [PET]-computed tomography [CT] scan defined as at least 1 lesion that measures >= 1.5 cm in single dimension). Gastrointestinal, bone marrow or spleen only patients are allowable"
NCT04189757,11,"Absolute neutrophil count (ANC) > 1,000/mm^3
* Patients who have bone marrow infiltration by mantle cell lymphoma (MCL) are eligible if their ANC is >= 500/mm^3 (growth factor allowed) or their platelet level is equal to or > 20,000/mm^3. These patients should be discussed with either the principal investigator (PI) or co-PI of the study for final approval"
NCT04189757,12,"Platelet count > 75,000/mm^3
* Patients who have bone marrow infiltration by MCL are eligible if their ANC is >= 500/mm^3 (growth factor allowed) or their platelet level is equal to or > 20,000/mm^3. These patients should be discussed with either the PI or co-PI of the study for final approval"
NCT04189757,13,Serum bilirubin < 1.5 mg/dl
NCT04189757,14,"Creatinine (Cr) clearance minimum to 30 mL/min per the Cockcroft-Gault formula as acalabrutinib pharmacokinetic (PK) has not been evaluated in patients with severe renal impairment (estimated glomerular filtration rate [eGFR] < 29 mL/min/1.7 3^m2, MDRD) or renal impairment requiring dialysis"
NCT04189757,15,Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) < 2.5 x upper limit of normal or < 5 x upper limit of normal if hepatic metastases are present. Gilbert’s disease is allowed
NCT04189757,16,"Disease free of prior malignancies with exception of currently treated basal cell, squamous cell carcinoma of the skin, carcinoma ""in situ"" of the cervix or breast, or other malignancies in remission (including prostate cancer patients in remission from radiation therapy, surgery or brachytherapy), not actively being treated with life expectancy of > 3 years. PI can use clinical judgement in the best interest of patients"
NCT04189757,17,"Women of childbearing potential (WOBP) must have a negative serum or urine pregnancy test. WOBP and males must be willing to use highly effective methods of birth control prior to starting therapy. Woman of childbearing potential (WOCBP) who are sexually active must use highly effective methods of contraception during treatment and for one week after the last dose of acalabrutinib. For male subjects with a pregnant or non-pregnant WOCBP partner, should use barrier contraception even if they have had a successful vasectomy"
NCT04189757,18,"Patients who were not placed originally on ibrutinib by the providers due to concerns for worsening of comorbidities due to ibrutinib, such as atrial fibrillation can be included after cardiology clearance"
NCT04219254,4,Has at least 1 measurable disease lesion as defined by Response Evaluation Criteria in Solid Tumors.
NCT04219254,9,For subjects whose tumor has PD-L1 ≥ 50%: Required prior therapies will include anti-PD-1 therapy as monotherapy. Prior standard of care chemotherapy will be allowed but not required.
NCT04219254,10,"For tumors with unknown PD-L1 or PD-L1 < 50% , required prior therapies will include anti-PD 1/PD-L1 therapy and SOC chemotherapy either combined with anti PD-1/PD-L1 therapy or given separately."
NCT04219254,11,"For subjects with known anaplastic lymphoma kinase, ROS1 or epidermal growth factor receptor (EGFR) sensitizing molecular rearrangements or with BRAF mutations, one line of targeted therapy will be required in addition to anti-PD1/ PD-L1 therapy. Cohort 2 (Metastatic Melanoma):"
NCT04219254,13,For subjects with a known BRAF V600-activating mutation combination targeted therapy will be required in addition to anti-PD-1/PD-L1 therapy. Cohort 3 (Other Tumor Types):
NCT04270175,2,Has received daratumumab or Faspro in any prior line of therapy
NCT04270175,3,Prior pomalidomide exposure allowed if ≥ PR achieved and no disease progression occurred within 60 days of last dose received
NCT04270175,8,Total bilirubin ≤ 1.5 × the upper limit of the normal range (ULN) (Total bilirubin ≥ 1.5 x ULN is acceptable if bilirubin is fractionated and direct bilirubin <35%)
NCT04270175,10,eGFR ≥ 20 mL/min/1.73 m2 (as calculated by Modified Diet in Renal Disease (MDRD) formula)
NCT04305834,6,"Histologically or cytologically confirmed diagnosis of:
* Estrogen-receptor positive and/or progesterone receptor positive breast cancer determined by immunohistochemistry (IHC) methods according to the local institution standard protocol
* HER2-negative breast cancer defined as negative if the IHC status is 0 or 1+, or if IHC is 2+ and in situ hybridization assay is negative per American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines"
NCT04305834,8,Progressed on prior endocrine therapy
NCT04305834,9,Progressed on palbociclib or ribociclib (not abemaciclib) in the metastatic setting or recurrence greater than 1 year of adjuvant abemaciclib therapy
NCT04305834,10,May have had chemotherapy in any line
NCT04305834,11,Patients who received chemotherapy must have recovered (Common Terminology Criteria for Adverse Events [CTCAE] grade =< 1) from the acute side effects of chemotherapy (except for residual alopecia or residual grade 2 peripheral neuropathy). A washout period of at least 21 days is required between last chemotherapy dose and registration (provided the patient did not receive radiotherapy)
NCT04305834,12,Patients who received radiotherapy must have completed and fully recovered from the acute effects of radiotherapy. A washout period of at least 14 days is required between end of radiotherapy and registration
NCT04305834,13,"Absence of central nervous system (CNS) involvement unless they meet ONE of the following criteria:
* Untreated brain metastases (e.g., lesions < 1 cm) not needing immediate local therapy
* Previously treated brain metastases not needing immediate local therapy
** At least 6 days from the last date of prior therapy completion (including radiation and/or surgery) to starting the study treatment
** Clinically stable CNS tumor at the time of screening and not receiving steroids and/or enzyme-inducing anti-epileptic medications for brain metastases"
NCT04305834,18,"In the absence of liver metastases, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3.0 x upper limit of normal (ULN)"
NCT04332367,3,Completion of minimum of 3 cycles of 1st-line chemoimmunotherapy. Patients who had pembrolizumab held for 1st cycle of combination therapy while awaiting molecular data are eligible
NCT04332367,4,"Progression after at least 12 weeks of maintenance pemetrexed/pembrolizumab, or pembrolizumab alone"
NCT04332367,14,"International normalized ratio (INR) =< 1.5, and a partial thromboplastin time (PTT) =< 5 seconds above the ULN (unless receiving anticoagulation therapy). Patients receiving warfarin must be switched to low molecular weight heparin or edoxaban or show stability on another Food and Drug Administration (FDA) approved oral anticoagulant with stable coagulation profile prior to first dose of protocol therapy. There may be no active bleeding (that is, no bleeding within 14 days prior to first dose of protocol therapy) or pathological condition present that carries a high risk of bleeding (for example, tumor involving major vessels or known varices)"
NCT04332367,15,"Serum creatinine =< 1.5 times the ULN; or if serum creatinine is > 1.5 times the ULN, creatinine clearance (measured via 24-hour urine collection) must be >= 40 mL/minute"
NCT04332367,17,"If sexually active, must be postmenopausal, surgically sterile, or using effective contraception (hormonal or barrier methods)"
NCT04337580,1,Patients must have castrate refractory prostate cancer with prior docetaxel treatment which was used in the castrate refractory setting
NCT04337580,6,Men must agree to use adequate contraception (barrier method of birth control; abstinence) prior to study entry and for the duration of study participation
NCT04337580,12,Creatinine < 2.5 X institutional upper limit of normal
NCT04340882,1,Male/female participants who are at least 18 years of age on the day of signing informed consent with histologically confirmed diagnosis of non-small cell lung cancer will be enrolled in this study
NCT04340882,2,"Patients must have progressed on a platinum-based chemotherapy and any of the Food and Drug Administration (FDA)-approved PD-1 or PD-L1 immune checkpoint inhibitors, either given sequentially or in combination"
NCT04340882,3,A male participant must agree to use a contraception during the treatment period plus an additional 120 days after the last dose of study treatment and refrain from donating sperm during this period
NCT04340882,6,Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. Lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions
NCT04340882,9,Absolute neutrophil count (ANC) >= 1500/uL (collected within 10 days prior to the start of study treatment)
NCT04340882,10,Platelets >= 100 000/uL (collected within 10 days prior to the start of study treatment)
NCT04340882,11,"Hemoglobin >= 9.0 g/dL or >= 5.6 mmol/L (collected within 10 days prior to the start of study treatment)
* Criteria must be met without erythropoietin dependency and without packed red blood cell (pRBC) transfusion within last 2 weeks"
NCT04340882,12,"Creatinine =< 1.5 x upper limit of normal (ULN) OR measured or calculated creatinine clearance (glomerular filtration rate [GFR] can also be used in place of creatinine or creatinine clearance [CrCl]) >= 30 mL/min for participant with creatinine levels > 1.5 x institutional ULN (collected within 10 days prior to the start of study treatment)
* Creatinine clearance (CrCl) should be calculated per institutional standard"
NCT04340882,13,Total bilirubin =< 1.5 x ULN OR direct bilirubin =< ULN for participants with total bilirubin levels > 1.5 x ULN (collected within 10 days prior to the start of study treatment)
NCT04340882,14,Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 x ULN (=< 5 x ULN for participants with liver metastases) (collected within 10 days prior to the start of study treatment
NCT04340882,15,Palliative radiotherapy (to bone or soft tissue lesions) must be completed > 1 week prior to start of study drug (exception: palliative radiotherapy for pain may be used any time prior to first dose)
NCT04340882,16,"Clinically significant toxic effect(s) of the most recent prior anti-cancer therapy must be grade 1 or resolved (except alopecia and sensory neuropathy); patients with grade 2 adrenal insufficiency related to prior anti-cancer therapy (defined as requiring medical intervention, such as concomitant steroids) or grade 2 hypothyroidism (defined as requiring hormone replacement therapy) may be enrolled provided that clinical symptoms are adequately controlled and the daily dose is 10 mg or less of prednisone or equivalent. If the patient received major surgery or radiation therapy of > 30 Gy, they must have recovered from the toxicity and/or complications from the intervention"
NCT04340882,17,Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial
NCT04375384,3,Patients must have received previous treatment with immunotherapy with PD-1 inhibitor alone or in combination with chemotherapy
NCT04407247,1,Patients who receive any type of immune checkpoint inhibitor (ICI) therapy
NCT04415944,1,"Patients must have histologically I-III epithelial carcinoma of the ovary, fallopian tube or peritoneum or stage IVA disease in which there is complete resolution of disease (pleural effusion) with chemotherapy"
NCT04415944,2,Patients must have undergone cytoreductive surgery and 3-8 cycles of platinum-based systemic chemotherapy prior to the second look surgery.  Systemic platinum based chemotherapy must be completed <18 weeks prior to second look surgery
NCT04415944,3,"Cytoreductive surgery must result in an R-0, R-1 resection prior to systemic chemotherapy"
NCT04415944,5,"Patients must be without clinical evidence of disease including a negative exam, imaging (computed tomography [CT] or positron emission tomography [PET/CT]) and normal tumor markers (CA125) after completion of systemic chemotherapy"
NCT04415944,14,Adequate contraception and negative pregnancy test if pregnancy possible
NCT04419519,4,"Receiving treatment or planning to receive treatment within 30 days with a venetoclax-based regimen as defined below:
* Venetoclax monotherapy
* Venetoclax in combination with anti CD20 monoclonal antibody"
NCT04419519,5,Patients must be receiving or plan to receive commercially supplied venetoclax (and anti CD20 monoclonal antibody)
NCT04419519,6,"Patient has or will have specimen to identify the CLL or SLL clone(s) for future MRD assessments by clonoSEQ defined as any of the following:
* 3-5 bone marrow aspirate slides (banked), 3-5 formalin-fixed paraffin-embedded (FFPE) slides (banked), banked tumor cells, or banked deoxyribonucleic acid (DNA) collected from the patient at any time from original diagnosis of CLL or SLL to present
* Peripheral blood, marrow, or lymph node involvement for fresh sample collection"
NCT04419519,7,The screening ID sample (high disease burden sample) can be sent prior to start of venetoclax-based therapy to identify the clone for tracking
NCT04419519,9,Patients must have received venetoclax-based therapy for at least 6 months (including dose interruptions)
NCT04419519,10,"If receiving venetoclax in combination with anti-CD20 monoclonal antibody, patients must have completed or discontinued the anti-CD20 monoclonal antibody portion of the regimen prior to discontinuing therapy"
NCT04419519,12,"Patients must have achieved a complete or partial remission with the venetoclax-based regimen. Criteria for remission are per International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2018 guidelines. For this protocol, bone marrow biopsy/aspirate evaluation is not necessary to determine remission status"
NCT04423211,3,Patient must have had a radical prostatectomy (RP) as definitive therapy for histopathologically-proven prostatic adenocarcinoma
NCT04423211,5,"Patients must have no definite evidence for extrapelvic metastatic disease. This may be determined by CIM (CT abdomen/pelvis or MRI abdomen/pelvis AND bone scintigraphy or equivalent) within 26 weeks prior to step 0 registration. If patient does not have prior CIM, an existing study-eligible = PET using FDA-approved radiotracer may be used to determine whether patient requires CIM.
For patients who have study-eligible PET done without prior CIM:
* Baseline CIM is required if the study-eligible PET is positive for extrapelvic lesions. Patient should have a baseline CT/MRI (e.g. for soft tissue lesions) and performed within 16 weeks prior to study registration./or a bone scan (e.g. for osseous lesions), for further evaluation of the PET-detected extrapelvic lesion(s).
* Baseline CIM is not required if the study-eligible PET is negative for extrapelvic lesions.
NOTE: Extra-pelvic metastases are defined as extrapelvic soft tissue, lymph node and organ metastases, and/or any osseous metastases; extra-pelvic is defined as superior to common iliac bifurcation, and/or outside of standard fields for prostate bed + whole pelvis nodal RT fields"
NCT04423211,6,Patient must be a candidate for SOC post-prostatectomy radiation therapy (RT) to the prostate bed and pelvic nodes with androgen deprivation therapy (ADT)
NCT04423211,9,"Patient must not have started short term ADT for biochemical recurrence prior to baseline PET (PET1), but may start short term ADT after PET and up to 7 days prior to study registration.
* NOTE:  A short course (e.g., ~ 4 weeks) of low-dose anti-androgen (e.g. bicalutamide), started given after PET1, either before or after study registration, is also permitted as a brief temporizing measure/bridge to protocol-approved SOC short term ADT"
NCT04423211,21,Creatinine < 1.5 x institutional ULN (or measured creatinine clearance > 30 mL/min) (obtained within 8 weeks prior to Step 0 registration)
NCT04423211,24,"Patient must not have completed a course of prior pelvic external beam radiation therapy that would overlap with SOC RT fields used in this protocol, such that normal tissue constraints cannot be met"
NCT04434040,1,"Pathologically confirmed residual invasive breast cancer, in the breast and/or lymph node(s), following neoadjuvant chemotherapy. In the absence of residual invasive disease in the breast, lymph node must contain at least 2 mm of invasive disease"
NCT04434040,4,Patients must have received neoadjuvant chemotherapy prior to breast surgery
NCT04434040,5,"Patients must be within 4 months of completion of all locoregional therapy (either last surgery or last dose of radiation, whichever is later). Definitive breast surgery must have been performed and includes lumpectomy or mastectomy with pathologically clear margins (i.e. no ink on tumor). For patients undergoing lumpectomy, this must be followed by whole breast irradiation. Definitive surgery also includes axillary surgery, either sentinel lymph node biopsy or axillary lymph node dissection at the discretion of the attending surgeon"
NCT04434040,6,"Evidence of ctDNA in blood sample collected after completion of all local and systemic neoadjuvant therapy (preoperative chemotherapy) surgery and radiation, confirmed by central testing. Detection of any tumor specific mutations (TSMs) within the sample will be considered positive for purposes of study eligibility"
NCT04434040,7,Concurrent receipt of bone modifying agents (bisphosphonates or rank-ligand inhibitors) is allowed
NCT04434040,8,Prior treatment with an immune checkpoint inhibitor in the neoadjuvant setting is permitted
NCT04434040,17,"Serum bilirubin =< 1.5 x institutional ULN with the following exception:
* Patients with known Gilbert syndrome: serum bilirubin level =< 3 x institutional ULN"
NCT04434040,18,Serum creatinine =< 1.5 x institutional ULN
NCT04434040,23,Women of childbearing potential (pre-menopausal) must have a negative serum or urine pregnancy test within 7 days prior to start of therapy. A woman is defined as pre-menopausal if she is less than 12 months from last menstrual period with no identified cause other than menopause (medication induced amenorrhea is not acceptable). Pregnancy test is not required in women who are surgically sterile via bilateral salpingo-oophorectomy or hysterectomy
NCT04434040,24,"Women of childbearing potential and men must agree to use adequate contraception for the duration of protocol treatment and for 6 months after last dose of atezolizumab and 6 months after last dose of sacituzumab govitecan, whichever is later. Hormonal contraceptives are not acceptable"
NCT04484012,2,"Participants must agree to allow the use of archival tissue from diagnostic tumor biopsies
* If unavailable, exceptions may be granted with study principal investigator (PI) approval
Note: For research participants who do not speak English, a short form consent may be used with a City of Hope (COH) certified interpreter/translator to proceed with screening and leukapheresis, while the request for a translated full consent is processed"
NCT04484012,5,"Documented CD19+ mantle cell lymphoma (MCL) by flow cytometry or immunohistochemistry (IHC) (from biopsy) if prior CD19 directed therapy was previously used
* BM is optional at enrollment IF patient already has biopsy proven disease"
NCT04484012,6,"Participants must be currently receiving acalabrutinib and have been taking acalabrutinib for between 3 and 7 months prior to initiating screening procedures on the study and:
* Must have failed at least 1 prior regimen before acalabrutinib (not including single‐agent corticosteroids)
* Best response to acalabrutinib therapy is MRD+ CR, partial response (PR) or stable response (SD) at the time of screening
** Must have measurable disease by computed tomography (CT) scan (>= 1.5 cm) or evidence of blood, spleen, skin, gastrointestinal (GI) or bone marrow involvement
Note: Participants who are on other BTK inhibitors, but will thereafter be switched to acalabrutinib prior to lymphodepletion, may be eligible provided that the duration of all BTK inhibitor therapy was =< 3-7 months"
NCT04484012,7,"No contraindications to leukapheresis, steroids or tocilizumab"
NCT04484012,8,Total serum bilirubin =< 2.0 mg/dL (performed within 28 days prior to enrollment)
NCT04484012,13,Alanine aminotransferase (ALT) < 3 x ULN (performed within 28 days prior to enrollment)
NCT04484012,15,International normalized ratio (INR) OR prothrombin (PT) =< 1.5 x ULN (performed within 28 days prior to enrollment)
NCT04484012,18,Cardiac function (12 lead‐electrocardiogram [ECG]): corrected QT (QTc) must be =< 480 msec
NCT04484012,20,Oxygen saturation 92% or above at room air or diffusion capacity of the lung for carbon monoxide (DLCO) of 40% of best predicted
NCT04484012,21,"Participants of reproductive potential must agree to use highly effective birth control methods throughout therapy and for 2 months after final CAR T cell infusion and/or 2 days after final acalabrutinib dose, whichever is later"
NCT04493203,4,"Progressed on prior anti-PD1 therapy with or without anti-CTLA4 therapy. Patients may have progressed in the adjuvant setting if treated within the last 6 months. Prior treatment with BRAF/MEK inhibitors permitted, however, not required. Progression must be radiographic, and progression of disease will be confirmed by a radiologist. Patients must have progressed during anti-PD-1 therapy, defined as unequivocal progression on or within 3 months of the last dose of anti-PD-1 therapy if treated in the metastatic setting, or within 6 months if treated in the adjuvant setting"
NCT04493203,5,Have measurable disease based on response evaluation criteria in solid tumors (RECIST) 1.1
NCT04493203,11,"Serum creatinine =< 1.5 X upper limit of normal (ULN) OR measured or calculated creatinine clearance 
(glomerular filtration rate [GFR] can also be used in place of creatinine or creatinine clearance [CrCl]*) >= 60 mL/min for subject with creatinine levels > 1.5 X institutional ULN (within 14 days of treatment initiation)
* Creatinine clearance should be calculated per institutional standard"
NCT04493203,19,"Male subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 7 months after the last dose of study therapy
* Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject"
NCT04508790,7,"Relapsed or refractory to at least 1 prior line of therapy, including both a proteasome inhibitor and an immunomodulatory drug, and for whom transplant is not recommended. Participants may opt for a delayed transplant at a later time, if appropriate"
NCT04508790,19,"All study participants must be registered into the mandatory POMALYST REMS program, and be willing and able to comply with the requirements of the Pomalyst Risk Evaluation and Mitigation Strategy (REMS) program"
NCT04527900,1,"Surgery must have included a hysterectomy. Bilateral salpingo-oophorectomy, pelvic lymph node sampling, para-aortic lymph node sampling, and omentectomy are optional"
NCT04527900,3,"Patients with endometrioid endometrial cancer with the following: 
* Stage IA grade 3 with extensive lymphovascular space invasion (LVSI) 
* Stage IB grade 3 
* Stage II 
* Stage III (A, B, and C) 
* Stage IVA who are recommended adjuvant whole pelvic radiation therapy (RT) (+/- lower para-aortic up to renal hilum) and systemic chemotherapy"
NCT04527900,4,"Patients with clear cell, serous papillary carcinoma, or carcinosarcoma with stages IA-III who are recommended adjuvant whole pelvic RT (+/- lower para-aortic up to renal hilum) and systemic chemotherapy"
NCT04527900,10,Bilirubin =< 1.5 x ULN
NCT04527900,11,"Creatinine =< institutional ULN (if serum creatinine > ULN, estimated glomerular filtration rate [GFR] >= 45 ml/min)"
NCT04548752,1,"Patients must have a histologic or cytologic diagnosis of pancreatic adenocarcinoma. Patients with neuroendocrine tumors, acinar cell and adenosquamous carcinomas are excluded. All disease must be assessed and documented on the Baseline Tumor Assessment Form"
NCT04548752,3,"Patients must have metastatic disease and received first line platinum-based chemotherapy (i.e. fluorouracil, irinotecan, leucovorin and oxaliplatin [FOLFIRINOX], leucovorin calcium, 5-fluorouracil, and oxaliplatin [FOLFOX], gemcitabine + nab-paclitaxel + cisplatin or gemcitabine + cisplatin)"
NCT04548752,4,Patients must have had a CT or MRI showing stable or responding disease on first line platinum-based chemotherapy within 30 days prior to registration
NCT04548752,5,Patients with known human immunodeficiency virus (HIV)-infection are eligible providing they are on effective anti-retroviral therapy and have undetectable viral load at their most recent viral load test and within 6 months prior to registration
NCT04548752,8,"Patients must have received at least 16 weeks of first line platinum-based chemotherapy for metastatic disease. Patients may have also received one cycle of treatment (no more than 4 weeks) with gemcitabine + nab-paclitaxel while waiting for germline test results, prior to platinum-based therapy"
NCT04548752,9,Patients’ last chemotherapy treatment must be within 30 days prior to registration
NCT04548752,10,"Patients must have resolved or stable =< grade 1 toxicity from prior administration of another investigational drug and/or prior anti-cancer treatment, excluding neuropathy and alopecia"
NCT04548752,11,Patients must not have a known hypersensitivity to olaparib or any of the excipients of the product
NCT04548752,12,Patients must not be planning to receive strong or moderate CYP3A inhibitors or inducers while on olaparib treatment. Patients receiving strong or moderate CYP3A inhibitors must discontinue use at least 2 weeks prior to receiving olaparib. Patients receiving strong or moderate CYP3A inducers must discontinue use at least 5 weeks prior to receiving olaparib. Medications should be checked using a frequently updated medical reference for a list of drugs to avoid
NCT04548752,13,"Patients must not have received live vaccines within 42 days prior to randomization and must not be planning to receive live virus or live bacterial vaccines while receiving study treatment and during the 30 day follow up period. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, chicken pox, shingles, yellow fever, rabies, Bacillus Calmette-Guerin (BCG), and typhoid (oral) vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (e.g., Flu-Mist) are live attenuated vaccines, and are not allowed. Coronavirus disease 2019 (COVID-19) messenger ribonucleic acid (mRNA) vaccine is allowed"
NCT04548752,14,"Patients must not have had prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent, or any other immune checkpoint inhibitors"
NCT04548752,15,Patients must not have had prior therapy with PARP inhibitors
NCT04548752,16,Patients must not have had a prior diagnosis of immunodeficiency or receiving systemic steroid therapy (defined as >= 10 mg prednisone or equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment
NCT04548752,19,Patients must have a complete medical history and physical exam within 28 days prior to registration
NCT04548752,23,Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3 x institutional ULN (within 14 days of registration)
NCT04548752,24,Albumin >= 3.0 g/dL (within 14 days of registration)
NCT04548752,27,Participants must have a serum creatinine =< the institutional (I)ULN OR measured OR calculated creatinine clearance >= 50 mL/min using the following Cockcroft-Gault Formula. This specimen must have been drawn and processed within 14 days prior to registration
NCT04548752,28,Patients must have CA19-9 obtained within 42 days prior to registration
NCT04548752,30,Participants with a prior or concurrent malignancy whose natural history or treatment (in the opinion of the treating physician) does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial provided it does not require concurrent therapy
NCT04548752,31,"Participants must not be pregnant or nursing due to the possibility of harm to the fetus or nursing infant from this treatment regimen. Women of childbearing potential must have a negative urine or serum pregnancy test within 28 days prior to registration. Women/men of reproductive potential must have agreed to use an effective contraceptive method for the course of the study through 6 months after the last dose of study medication. A woman is considered to be of ""reproductive potential"" if she has had menses at any time in the preceding 12 consecutive months. In addition to routine contraceptive methods, ""effective contraception"" also includes heterosexual celibacy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy, bilateral oophorectomy or bilateral tubal ligation. However, if at any point a previously celibate participant chooses to become heterosexually active during the time period for use of contraceptive measures, he/she is responsible for beginning contraceptive measures. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately"
NCT04548752,32,Patients must not have a history of (non-infectious) pneumonitis that required steroids or current pneumonitis
NCT04548752,33,Patients must not have an active infection requiring systemic therapy
NCT04548752,34,"Patients must not have active autoimmune disease that has required systemic treatment in past 2 years (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment"
NCT04548752,35,"Patients must be offered the opportunity to participate in specimen banking of formalin-fixed paraffin-embedded (FFPE) tissue and whole blood. If a patient is unable to submit archival tissue, should the patient need to undergo a standard of care biopsy per National Comprehensive Cancer Network (NCCN) guidelines, patients must then be offered the opportunity to submit the fresh tumor tissue from that biopsy. With participant consent, specimens must be collected and submitted via the Southwest Oncology Group (SWOG) Specimen Tracking System"
NCT04548752,37,As a part of the Oncology Patient Enrollment Network (OPEN) registration process the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system
NCT04567771,2,"Must have undergone an open or robotic hysterectomy (total abdominal, vaginal, radical, or total laparoscopic) for carcinoma of the cervix or endometrium"
NCT04567771,9,"Computed tomography (CT), magnetic resonance imaging (MRI), positron emission tomography (PET)/CT, or PET/MRI for staging before registration; may be pre-operative (op) or post-op"
NCT04579224,3,Participant must have had progression of disease following prior therapy at the discretion of the treating investigator
NCT04579224,5,"Participant must have had prior systemic therapy in metastatic setting that:   
* Included enfortumab vedotin 
* Included a PD1/PDL1 antibody
** NOTE: Under the discretion of the treating physician, participants who are not candidates for PD1/PDL1 antibody systemic therapy are allowed
* Any systemic therapy provided in adjuvant, neoadjuvant, or chemoradiation settings for urothelial carcinoma can be considered to be in metastatic setting, if the last day of treatment was within 12 months prior to the diagnosis of metastatic disease"
NCT04579224,6,Participant must have completed any planned surgery or radiation therapy prior to registration
NCT04579224,7,Participant must not have unresolved toxicities from prior surgeries or radiation therapy > grade 1 at the time of registration
NCT04579224,18,Participants must not be planning to take strong or moderate CYP3A or CYP2C8 inhibitors or inducers if randomized to Arm 1 and standard of care (SOC) regimen chosen is paclitaxel or docetaxel. Participants receiving strong or moderate CYP3A- or CYP2C8 inducers must discontinue use at least 2 weeks prior to randomization
NCT04579224,20,"Participants must not be pregnant or nursing due to the risk of harm to a fetus or nursing infant. Women and men of reproductive potential must have agreed to use an effective contraceptive method for the course of the study and 6 months (females) or 3.5 months (males) after the last dose. A woman is considered to be of ""reproductive potential"" if she has had menses at any time in the preceding 12 consecutive months. In addition to routine contraceptive methods, ""effective contraception"" also includes heterosexual celibacy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy, bilateral oophorectomy or bilateral tubal ligation. However, if at any point a previously celibate participant chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol, he/she is responsible for beginning contraceptive measures"
NCT04585958,1,DOSE ESCALATION PHASE
NCT04585958,2,Patients must have histologically confirmed malignancy that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective
NCT04585958,3,"Patients must have HER2-positive or HER2-expressing tumors determined by a Clinical Laboratory Improvement Act (CLIA)-certified laboratory. Specific requirement of HER2 status is outlined below:
* Dose Escalation Module 1 and Module 2:
** HER2 1-3+ expression by IHC OR
** HER2 amplification by next generation sequencing panel (NGS) or in situ hybridization (ISH) OR
** If local testing is not feasible, patients will submit archival tissue for central HER2 testing to determine eligibility. Patients with unknown or negative HER2 testing will not be eligible
* Dose Escalation Module 3:
** HER2 1-2+ expression by IHC OR
** HER2 amplification by next generation sequencing panel (NGS) or in situ hybridization (ISH) OR
** If local testing is not feasible, patients will submit archival tissue for central HER2 testing to determine eligibility. Patients with unknown or negative HER2 testing will not be eligible"
NCT04585958,5,"Patients must have histologically confirmed platinum resistant, high grade serous ovarian carcinoma. Platinum resistant is defined as radiographic progression < 6 months following the last dose of platinum therapy, or serologic progression (per Gynecological Cancer Intergroup [GCIG] cancer antigen 125 [CA125] criteria) < 6 months following the last dose of platinum therapy"
NCT04585958,7,There must be least one lesion suitable for biopsy without significant risk to the patient
NCT04585958,8,Patient disease must be evaluable or measurable by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Biopsiable lesion cannot be the only RECIST-measurable lesion
NCT04585958,9,DOSE ESCALATION AND DOSE EXPANSION PHASES
NCT04585958,10,Patients must have had at least one prior line of cytotoxic chemotherapy
NCT04585958,11,"Patients can have received an unlimited number of additional lines of chemotherapy, targeted therapy, biologic therapy, or hormonal therapy"
NCT04585958,13,"Age >= 18 years. Because no dosing or adverse event data are currently available on the use of DS-8201a in combination with olaparib in patients < 18 years of age, children are excluded from this study"
NCT04585958,16,"Absolute neutrophil count >= 1,000/mcL (within 14 days of randomization/enrollment)
* No administration of granulocyte colony-stimulating factor (G-CSF) is allowed within 1 week prior to screening assessment"
NCT04585958,19,Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 3 x institutional ULN (within 14 days of randomization/enrollment)
NCT04585958,20,"International normalized ratio (INR)/prothrombin time (PT) and activated partial thromboplastin time (aPTT) =< 1.5 x ULN (unless therapeutically anticoagulated) (within 14 days of randomization/enrollment)
* Dose expansion only. Coagulation parameter requirement is not applicable for the dose escalation"
NCT04585958,21,Creatinine =< 1.5 x institutional ULN (within 14 days of randomization/enrollment) OR
NCT04585958,23,Patients must have left ventricular ejection fraction (LVEF) >= 50% by either an echocardiogram (ECHO) or multigated acquisition (MUGA) scan within 28 days before randomization/enrollment
NCT04585958,24,"Patients who are human immunodeficiency virus (HIV) positive may participate IF they meet the following eligibility requirements:
* They must be stable on their anti-retroviral regimen, and they must be healthy from an HIV perspective 
* They must have an undetectable viral load and a CD4 count >= 250 cells/uL within 7 days of enrollment
* They must not be currently receiving prophylactic therapy for an opportunistic infection and must not have had an opportunistic infection within the past 6 months
* HIV-infected patients should be monitored every 12 weeks for viral load and CD4 counts"
NCT04585958,25,"For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated"
NCT04585958,27,Patients with brain metastases should be stable and off steroids and at least 4 weeks from radiation at the time of registration
NCT04585958,28,Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial
NCT04585958,30,"The effects of DS-8201a and olaparib on the developing human fetus are unknown. For this reason and because HER2 antibody conjugated to a topoisomerase 1 inhibitor agents as well as PARP inhibitors are known to be teratogenic; thus, women of child-bearing potential and men must agree to use highly effective contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for at least 7 months (women of childbearing potential [WOCBP] only) after the last dose of study drug. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of DS-8201a and olaparib administration"
NCT04585958,31,"Women of non-child-bearing potential defined as pre-menopausal females with a documented tubal ligation or hysterectomy; or postmenopausal defined as 12 months of spontaneous amenorrhea (in questionable cases, a blood sample with simultaneous follicle-stimulating hormone [FSH] > 40 mIU/mL and estradiol < 40 pg/mL [< 147 pmol/L] is confirmatory) are eligible. Females on hormone replacement therapy (HRT) and whose menopausal status is in doubt will be required to use one of the contraception methods outlined for women of child-bearing potential if they wish to continue their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of post-menopausal status prior to study enrollment. For most forms of HRT, at least 2-4 weeks will elapse between the cessation of therapy and the blood draw; this interval depends on the type and dosage of HRT. Following confirmation of their post-menopausal status, they can resume use of HRT during the study without use of a contraceptive method"
NCT04585958,32,"Male subjects must not freeze or donate sperm starting at screening and throughout the study period, and at least 4 months after the final study drug administration. Preservation of sperm should be considered prior to enrollment in this study"
NCT04585958,33,"Female subjects must not donate, or retrieve for their own use, ova from the time of screening and throughout the study treatment period, and for at least 7 months after the final study drug administration"
NCT04585958,34,Ability to understand and the willingness to sign a written informed consent document. Participants with impaired decision-making capacity (IDMC) who have a legally-authorized representative (LAR) and/or family member available will also be eligible
NCT04599140,10,"Received at least two prior regimens of therapy for unresectable or metastatic CRC including fluoropyrimidine-, oxaliplatin-, and irinotecan-based regimens. Patients who relapse within 6 months of adjuvant chemotherapy composed of oxaliplatin and a fluoropyrimidine will have their adjuvant therapy count as one prior regimen"
NCT04599140,11,"For the expansion cohort, pre-treatment primary tumor tissue (i.e., archived paraffin embedded) or from an unresectable metastatic site must be available for biomarker analyses. Biopsy should be excisional or core needle. Fine needle aspirates or other cytology samples are insufficient"
NCT04599140,13,Must have measurable disease with at least 1 unidimensional measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1
NCT04599140,19,Creatinine =< 1.5 mg/dL (should be obtained within 14 days prior to first dose)
NCT04599140,21,"Bilirubin < 1.5 mg/dL (unless diagnosed with Gilbert’s syndrome, who can have total bilirubin < 3.0 mg/dL) (should be obtained within 14 days prior to first dose)"
NCT04665947,4,"Confirmed presence of locally advanced, unresectable or metastatic pancreatic adenocarcinoma (other pancreatic malignant histologies are excluded) with measurable disease per RECIST (version 1.1) (i.e. at least 1 lesion > 1 cm or lymph node > 1.5 cm in short axis)"
NCT04665947,5,Participant must have documented tumor progression during or following at least one prior systemic regimen as established by diagnostic imaging
NCT04665947,7,Participant must have completed prior chemotherapy at least 2 weeks (washout period) prior to [68Ga]Ga DOTA 5G PET scan. Any clinically significant toxicity (with the exceptions of hair loss and sensory neuropathy) related to prior therapy resolved to grade 1 or baseline
NCT04665947,11,"Aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase =< 5 times upper limit of normal (ULN)"
NCT04665947,13,Creatinine =< 2 times ULN
NCT04665947,16,[177Lu]Lu DOTA-ABM-5G INCLUSION CRITERIA:
NCT04665947,17,Completion of entry into [68Ga]Ga DOTA-5G PET study and completion of scan
NCT04665947,18,The presence of at least one measurable disease by [68Ga]Ga DOTA-5G PET/CT (SUVmax > 2-fold above normal lung or liver)
NCT04671667,3,Patient must have undergone surgery with gross total resection and must be randomized within 8 weeks of surgery
NCT04671667,5,Patient must have a PD-L1 Combined Positive Score (CPS) >= 1 in a Clinical Laboratory Improvement Act (CLIA) certified laboratory. Testing can be done locally as long as it is done in a CLIA certified laboratory. This testing must be on the tumor specimen from the resection of the patient’s recurrent or second primary HNSCC
NCT04671667,6,Patient must have had prior radiation to the area of recurrent or second primary tumor. This is defined as > 50% of the presurgical tumor volume having previously received a dose of > 45 Gy as determined by the treating radiation oncologist
NCT04671667,7,Patient must have completed prior radiation a minimum of 6 months prior to randomization
NCT04671667,8,Patient must not have any evidence of distant disease based on baseline imaging done within 28 days prior to randomization
NCT04671667,9,"Patient must not have received anti-PD-1/PD-L1 therapy for recurrent disease. If the patient received anti-PD-1/PD-L1 therapy as part of initial upfront curative intent treatment (either as part of definitive non-surgical therapy or in the adjuvant setting) in the past, the last dosage of anti-PD-1/PD-L1 therapy must have been given greater than one year prior to randomization"
NCT04671667,11,Patient must have the ability to understand and the willingness to sign a written informed consent document. Patients with impaired decision-making capacity (IDMC) who have a legally authorized representative (LAR) or caregiver and/or family member available will also be considered eligible
NCT04671667,12,"Patient must not be pregnant or breast-feeding due to the potential harm to an unborn fetus and possible risk for adverse events in nursing infants with the treatment regimens being used. All patients of childbearing potential must have a blood test or urine study within 14 days prior to randomization to rule out pregnancy. A urine or serum pregnancy test must be repeated within 72 hours prior to receiving the first dose of pembrolizumab or chemotherapy if the test done for eligibility/randomization is done outside of this 72 hour window. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required. A patient of childbearing potential is someone, regardless of whether they have undergone tubal ligation, who meets the following criteria: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy; or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)"
NCT04671667,13,"Patient must not expect to conceive or father children by using by using accepted and effective method(s) of contraception or by abstaining from sexual intercourse while on study treatment, and continue for 120 days after the last dose of study treatment"
NCT04671667,17,Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 3.0 x institutional ULN (obtained =< 28 days prior to protocol randomization)
NCT04671667,20,Patient must not have a history of non-infectious pneumonitis requiring steroids within 3 years prior to randomization
NCT04671667,21,Patient must not have a history of solid organ transplant or stem cell transplant
NCT04671667,22,"Patient must not be on immunosuppressive medication within 7 days prior to randomization, EXCEPT for the following: a) intranasal, inhaled, topical steroids, or local steroid injection (e.g., intra-articular injection); b) systemic corticosteroids at physiologic doses =< 10 mg/day of prednisone or equivalent; c) steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication)"
NCT04671667,24,"Patient must not have received a live vaccine within 30 days prior to the first dose of study drug. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette–Guerin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (e.g., FluMist [registered trademark]) are live attenuated vaccines and are not allowed"
NCT04671667,25,Patient must not have severe hypersensitivity (>= grade 3) to pembrolizumab and/or any of its excipients
NCT04671667,26,"Patient must not have an active autoimmune disease that has required systemic treatment in past 2 years (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is allowed"
NCT04671667,28,Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial as long as they have not been HIV-infected with a history of Kaposi sarcoma and/or multicentric Castleman disease
NCT04671667,29,"Patient must not have a known history of hepatitis B (defined as hepatitis B surface antigen [HBsAg] reactive) or known active hepatitis C virus (defined as HCV ribonucleic acid [RNA] [qualitative] is detected) infection
* NOTE: No testing for hepatitis B and hepatitis C is required unless mandated by a local health authority"
NCT04691817,5,"No evidence of an EGFR, ALK, ROS1, BRAF or other driver mutation for which targeted therapy would be preferable or standard of care (consult principal investigator if there is a question of the nature of the mutation)"
NCT04691817,6,"Prior exposure and disease progression during at least 1 line of therapy including a checkpoint inhibitor. This may include a single checkpoint inhibitor, therapy with two checkpoint inhibitors simultaneously, or chemotherapy and immunotherapy combined or in sequence and must be the line immediately prior to enrollment on the trial. Prior PD-L1 inhibitors are permitted, since the goal of the study is to see if interleukin (IL) 6 inhibition can relieve resistance to immune checkpoint inhibitors"
NCT04691817,7,"No greater than CTCAE v5 grade 3 toxicity on prior immune checkpoint inhibitor therapy that was at least possibly attributable to prior immune checkpoint therapy, in the investigator’s opinion"
NCT04691817,8,Resolution of all immune related adverse events on prior immunotherapy to grade 1 or less
NCT04691817,10,"Availability of a representative paraffinized tumor specimen for exploratory biomarker research. A formalin-fixed paraffin-embedded (FFPE) tumor specimen in a paraffin block (preferred) or at least 10-15 slides containing unstained, freshly cut, serial sections should be submitted along with an associated pathology report prior to study enrollment. PDL1 status, which should be done as a standard of care for first line immunotherapy, will be recorded on a case report form. A biopsy may also be performed at screening if a patient's archival tissue test results do not meet eligibility criteria"
NCT04691817,17,"Serum bilirubin =< 1.5 x ULN with the following exception:
* Patients with known Gilbert disease: serum bilirubin level =< 3 x ULN"
NCT04691817,18,Serum creatinine =< 1.5 x ULN or Creatinine clearance >= 60 mL/min (calculated using the Cockcroft-Gault formula)
NCT04691817,22,"No untreated or actively progressing central nervous system (CNS) metastases. Patients with a history of treated CNS lesions are eligible, provided that all of the following criteria are met:
* Measurable disease, per RECIST v1.1, must be present outside the CNS
* The patient has no history of intracranial hemorrhage or spinal cord hemorrhage
* Metastases are limited to the cerebellum or the supratentorial region (i.e., no metastases to the midbrain, pons, medulla, or spinal cord)
* There is no evidence of interim progression between completion of CNS-directed therapy and the screening brain scan
* The patient has not received stereotactic radiotherapy within 7 days prior to initiation of study treatment or whole-brain radiotherapy within 14 days prior to initiation of study treatment
* The patient has no ongoing requirement for corticosteroids as therapy for CNS disease. Anticonvulsant therapy at a stable dose is permitted
* Asymptomatic patients with CNS metastases newly detected at screening are eligible for the study after receiving radiotherapy or surgery, with no need to repeat the screening brain scan"
NCT04691817,25,"No active or history of autoimmune disease or immune deficiency, including, but not limited to: myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, antiphospholipid antibody syndrome, Wegener granulomatosis, Sjögren syndrome, Guillain-Barré syndrome, or multiple sclerosis, with the following exceptions:
* Patients with a history of autoimmune-related hypothyroidism who are on thyroid-replacement hormone are eligible for the study
* Patients with controlled type 1 diabetes mellitus who are on an insulin regimen are eligible for the study
* Patients with eczema, psoriasis, lichen simplex chronicus, or vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis are excluded) are eligible for the study provided all of following conditions are met:
** Rash must cover < 10% of body surface area
** Disease is well controlled at baseline and requires only low-potency topical corticosteroids
** No occurrence of acute exacerbations of the underlying condition requiring psoralen plus ultraviolet A radiation, methotrexate, retinoids, biologic agents, oral calcineurin inhibitors, or high-potency or oral corticosteroids within the previous 12 months"
NCT04691817,26,"No history of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan
* History of radiation pneumonitis in the radiation field (fibrosis) is permitted"
NCT04691817,29,"No evidence of active hepatitis C virus (HCV) infection, defined as having a positive HCV antibody test followed by a positive HCV ribonucleic acid (RNA) test at screening
* The HCV RNA test will be performed only for patients who have a positive HCV antibody test"
NCT04691817,34,"No major surgical procedure other than for diagnosis within 4 weeks prior to initiation of study treatment, or anticipation of need for a major surgical procedure during the course of the study"
NCT04691817,39,No prior allogeneic stem cell or solid organ transplantation
NCT04691817,42,"No treatment with systemic immunosuppressive medication (including, but not limited to, corticosteroids, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti−TNF-⟨agents) within 2 weeks prior to initiation of study treatment, or anticipation of need for systemic immunosuppressive medication during the course of the study, with the following exceptions:
* Patients who received acute, low-dose systemic immunosuppressant medication or a one-time pulse dose of systemic immunosuppressant medication (e.g., 48 hours of corticosteroids for a contrast allergy) are eligible for the study, after obtaining principal investigator approval
* Patients who received mineralocorticoids (e.g., fludrocortisone), corticosteroids for chronic obstructive pulmonary disease (COPD) or asthma, or low-dose corticosteroids for orthostatic hypotension or adrenal insufficiency are eligible for the study"
NCT04691817,43,No requirement for use of denosumab during the study. Patients who are receiving denosumab for any reason (including hypercalcemia) must be willing and eligible to receive a bisphosphonate instead while in the study
NCT04691817,45,No known allergy or hypersensitivity to Chinese hamster ovary cell products or to any component of the atezolizumab or tocilizumab formulations
NCT04691817,47,"Agreement to follow appropriate contraception guidelines: Requirements for contraception and pregnancy testing for a clinical trial should encompass all investigational medicinal products (IMPs) as well as protocol-mandated non-investigational medicinal products (NIMPs) such as background therapy, and the measures to be followed should be based on the medicinal product with the highest risk. Contraception requirements for marketed IMPs or NIMPs should be based on recommendations in the Summary of Product Characteristics (SmPC) or, if there is no SmPC, national prescribing information. Length of time required for abstinence or use of contraceptives should take into account the reproductive toxicity profile, including genotoxicity and teratogenicity, the size of the molecule, and the number of doses. In the absence of specific delayed-toxicity concerns or safety hypotheses, the following guidelines should be used:
* Single dose studies: 
** Small molecules: 5 elimination half-lives or 14 days after the last dose, whichever is longer
** Large molecules: 2 elimination half-lives or 28 days after the last dose, whichever is longer
* Multiple dose studies:
** Small molecules: 5 elimination half-lives or 28 days after the last dose, whichever is longer
** Large molecules: 2 elimination half-lives or 28 days after the last dose, whichever is longer"
NCT04691817,48,"For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods, as defined below: Women must remain abstinent or use contraceptive methods with a failure rate of < 1% per year during the treatment period and for 5 months after the final dose of atezolizumab. A woman is considered to be of childbearing potential if she is post-menarche, has not reached a postmenopausal state (>= 12 continuous months of amenorrhea with no identified cause other than menopause), and has not undergone surgical sterilization (removal of ovaries and/or uterus) or another cause as determined by the investigator (e.g., Müllerian agenesis). Per this definition, a woman with a tubal ligation is considered to be of childbearing potential. The definition of childbearing potential may be adapted for alignment with local guidelines or requirements. Examples of contraceptive methods with a failure rate of < 1% per year include bilateral tubal ligation, male sterilization, hormonal contraceptives that inhibit ovulation, hormone-releasing intrauterine devices, and copper intrauterine devices. The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or post-ovulation methods) and withdrawal are not acceptable methods of contraception. If required per local guidelines or regulations, locally recognized adequate methods of contraception and information about the reliability of abstinence will be described in the local informed consent form
For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use a condom, and agreement to refrain from donating sperm, as defined below: With a female partner of childbearing potential or pregnant female partner, men must remain abstinent or use a condom during the treatment period and for 5 months after the final dose of atezolizumab to avoid exposing the embryo. Men must refrain from donating sperm during this same period. The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not adequate methods of preventing drug exposure. If required per local guidelines or regulations, information about the reliability of abstinence will be described in the local informed consent form"
NCT04713046,3,"PATIENT: Have a human leukocyte antigen (HLA) partially mismatched (haploidentical) related donor. Acceptable donors include first degree relatives (parent, child, or haploidentical sibling), half-siblings, or second degree relatives (aunt, uncle, cousin, niece, nephew). A patient who has inherited a recombinant haplotype from the parents is eligible if the donor shares at least 1 HLA antigen at each of the HLA-A, -B, and DR loci"
NCT04713046,4,PATIENT: Prior treatment with a platinum-containing regimen
NCT04713046,5,PATIENT: Patients with a Food and Drug Administration (FDA)-approved indication to receive an anti-programmed cell death protein-1 (PD-1) or anti-programmed death-ligand 1 (PD-L1) monoclonal antibody must have received at least one cycle of this therapy prior to receiving treatment on this trial
NCT04713046,7,PATIENT: Measurable disease using Response Evaluation Criteria In Solid Tumors (RECIST) 1.1. Tumor lesions situated in a previously irradiated area are considered measurable if progression has been documented in such lesions
NCT04713046,12,PATIENT: Serum creatinine =< 3.0 mg/dl
NCT04713046,34,DONOR: Donors whose product will be collected by simple phlebotomy (≤ 10^6 CD4+ T cells/kg recipient [recip.] ideal body weight [IBW]) must meet selection criteria established by the American Association of Blood Banks (AABB) and by the United States (U.S.) Food and Drug Administration (FDA). Donors of leukapheresis products must meet the selection criteria established by the Foundation for the Accreditation of Cellular Therapy (FACT) and the FDA
NCT04713046,35,"DONOR: Donor must meet eligibility criteria for allogeneic donors as described in the Johns Hopkins Hospital, Bone Marrow Transplant (BMT) and Cellular Therapy Policies and Procedures Patient/Donor Screening policy number DON003 “Eligibility of Allogeneic Donor”"
NCT04742634,1,MYELOSEQ-HD ASSAY (STEP 1)
NCT04742634,2,"Diagnosis of myelodysplastic syndromes (MDS) based on World Health Organization classification (2016 revision) who have received an allogeneic hematopoietic cell transplant. Any stem cell source, conditioning regimen, and immunosuppression regimen as determined by the treating physician, per institutional guidelines, is permitted. Patients may have received any therapy, or no therapy, prior to transplant."
NCT04742634,4,"Must have undergone gene panel testing prior to the start of transplant conditioning and must have at least one somatically acquired mutation that is interrogated by the MyeloSeq-HD panel. If the patient has a variant that is known to be a germline/inherited myeloid predisposition gene in that patient, this variant cannot and will not be used as evidence of MRD positivity. If the pre-transplant gene panel testing is a next-generation sequencing panel other than the MyeloSeq platform, the outside report will be reviewed by the principal investigator (PI) and the molecular pathologists at the McDonnell Genome Institute to ensure eligibility."
NCT04742634,5,=< 5 % bone marrow myeloblasts on the Day 30 post-transplant biopsy.
NCT04742634,6,"Willing to comply with the treatment assignment:
* Intent to proceed with DEC-C therapy if one or more variants detected prior to transplant persists at Day 30 post-transplant with a variant allele frequency of >= 0.5%.
* Intent to proceed with standard of care as determined by the treating physician on the observation arm (no DEC-C intervention) if no variants detected prior to transplant persist at Day 30 post-transplant with a variant allele frequency of >= 0.5%."
NCT04742634,8,DEC-C INTERVENTION ARM (STEP 2A)
NCT04742634,9,"One or more somatically acquired variants that were present prior to transplant detected by the MyeloSeq-HD panel at Day 30 post-transplant, with a variant allele frequency of >= 0.5%."
NCT04742634,10,Within Days 42-100 post-transplant.
NCT04742634,13,Only patients with adequately controlled graft versus host disease (GVHD) =< Grade 2 are eligible for the DEC-C intervention arm. Patients with active grade 3 or higher GVHD are ineligible for the DEC-C intervention arm.
NCT04742634,15,"Total bilirubin =< 1.5 x institutional upper limit of the normal (IULN).
* NOTE: If, in the opinion of the treating physician, bilirubin is elevated secondary to hemolysis or Gilbert’s disease, the patient may be eligible after discussion with the Washington University PI."
NCT04742634,16,Aspartate aminotransferase (AST)(serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT)(serum glutamate pyruvate transaminase [SGPT]) =< 3.0 IULN.
NCT04742634,18,"Decitabine has been shown to be teratogenic in animal studies and the use of intravenous (IV) decitabine in the first trimester of pregnancy has been associated with major birth defects. Women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control, abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately. Men and women treated or enrolled in this protocol must also agree to use adequate contraception prior to the study, for the duration of the study, and 6 months after completion of the study."
NCT04742634,19,OBSERVATION ARM (STEP 2B)
NCT04742634,20,Either =< 5 % bone marrow myeloblasts on the Day 30 post-transplant biopsy or enrolled in the study with > 5% bone marrow myeloblasts on the Day 30 post-transplant biopsy but not meeting eligibility criteria for the intervention arm.
NCT04768426,3,Residual disease following at least 4 cycles of neoadjuvant chemotherapy. Patients who received other investigational immunotherapy or targeted therapy during the neoadjuvant phase of treatment are eligible
NCT04768426,8,A minimum 4-week wash out from previous chemotherapy treatment is required (this does not apply for patients receiving low dose capecitabine with radiation); patients receiving adjuvant pembrolizumab are eligible
NCT04768426,9,Has completed adjuvant radiation if planned. Patients who received low dose capecitabine concurrent with radiation as a radiosensitizer are eligible
NCT04768426,12,Bilirubin =< 1.5 times the specific institutional upper limit of normal (ULN). Exception: If Gilbert’s syndrome; then =< 5 times ULN
NCT04768426,14,Serum creatinine =< 1.5 x ULN; or calculated creatinine clearance > 50 mL/min using the Cockcroft Gault formula
NCT04768426,15,Planned for 6 months or 8 cycles of adjuvant capecitabine (this can be given as monotherapy or concurrent with adjuvant pembrolizumab)
NCT04768426,17,WOCBP must agree to use effective contraception during the study and for 3 months after the last dose
NCT04768426,18,Male participants and their female partners of child bearing potential must be willing to use an appropriate method of contraception during the study and for 3 months after the last dose
NCT04768426,20,Patients must enroll within 8 weeks of completion of definitive surgery or adjuvant radiotherapy if indicated
NCT04781192,4,Progressed on at least one line of therapy (no restrictions on type of previous treatment)
NCT04781192,6,Measurable disease with at least 1 lesion that qualifies as a Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 target lesion (TL) at baseline. Previously irradiated lesion cannot be considered as target lesion (TL) except in cases of documented progression of the lesion since the completion of radiation therapy
NCT04781192,7,"Histologically confirmed unresectable or metastatic intrahepatic/extrahepatic cholangio‐ carcinoma or gallbladder cancer with radiographic progression, who have progressed on one line of therapy / failed adjuvant therapy"
NCT04781192,10,"Previous treatment with a programmed death 1 (PD1), programmed death-ligand (PD-L1), or cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitors, or agent directed to another co-inhibitory T cell receptor will be allowed"
NCT04781192,15,Creatinine < 1.5 x upper limit of normal (ULN) measured creatinine clearance (CL) > 40 mL/min or calculated creatinine CL> 40 mL/min by the Cockcroft‐Gault formula or by 24‐hour urine collection for determination of creatinine clearance
NCT04781192,17,"Total bilirubin =< 1.5 x institutional upper limit of normal, (biliary stenting or percutaneous biliary drainage are allowed for cancer related biliary obstruction)
* Exception: Patients with confirmed Gilbert’s syndrome (persistent or recurrent hyperbilirubinemia that is predominantly unconjugated in the absence of hemolysis or hepatic pathology), who will be allowed only in consultation with their physician"
NCT04781192,22,"Concomitant anticoagulation with oral anticoagulants with direct thrombin factor Xa inhibitors or platelet inhibitors (e.g., clopidogrel) will be allowed and managed per institutional guidelines provided that no prior evidence of clinically significant bleeding in the last 6 months. Warfarin will NOT be allowed"
NCT04781192,24,"Women of child‐bearing potential and men with partners of child‐bearing potential must agree to use an acceptable form of contraception for the duration of study participation, and for 7 months after the last study treatment"
NCT04852887,5,"The patient must have undergone a lumpectomy and the margins of the resected specimen or re-excision must be histologically free of invasive tumor and breast ductal carcinoma in situ (DCIS) with no ink on tumor as determined by the local pathologist. If pathologic examination demonstrates tumor at the line of resection, additional excisions may be performed to obtain clear margins. (Patients with margins positive for breast lobular carcinoma in situ [LCIS] are eligible without additional resection)"
NCT04852887,9,"Oncotype DX Recurrence Score of =< 18 on diagnostic core biopsy or resected specimen.
* For patients with a T1a tumor (=< 0.5 cm in size), or patients at Canadian provinces or approved international sites where Oncotype DX Recurrence Score testing would not be covered, who do not already have an Oncotype DX Recurrence Score at pre-entry/Step 1, a specimen (unstained blocks or slides) must be sent to the Genomic Health centralized laboratory. Tumor size sample must be ≥ 0.2 cm for analysis
* The Oncotype RS can be run on the biopsy core or surgical specimen. The patient cannot have initiated endocrine therapy prior to tissue collection.
* An Oncotype RS is required for eligibility, however, for a patient whose tumor has already had a MammaPrint test completed as part of usual care when being considered for enrollment and is in the binary “low” category will meet this eligibility criteria and an Oncotype RS does not need to be performed"
NCT04852887,12,"Patients may be premenopausal or postmenopausal at the time of pre-entry/Step 1. For study purposes, postmenopausal is defined as:
* Age 56 or older with no spontaneous menses for at least 12 months prior to pre-entry/Step 1; or a documented hysterectomy; or
* Age 55 or younger with no spontaneous menses for at least 12 months prior to pre-entry/Step 1 (e.g., spontaneous or secondary to hysterectomy) and with a documented estradiol level in the postmenopausal range according to local institutional/laboratory standard; or
* Documented bilateral oophorectomy"
NCT04852887,13,The interval between the last surgery for breast cancer (including re-excision of margins) and pre-entry/Step 1 must be no more than 70 days
NCT04852887,17,Patients must be intending to take endocrine therapy for a minimum 5 years duration (tamoxifen or aromatase inhibitor). The specific regimen of endocrine therapy is at the treating physician’s discretion
NCT04858009,7,Serum creatinine =< 1.5 mg/dL
NCT04858009,8,"Distant metastatic disease of peritoneum may be visualized on imaging:
* Positive peritoneal cytology
* Limited carcinomatosis on diagnostic laparoscopy or laparotomy
* KRASD assay positive peritoneal washings/cytology"
NCT04858009,9,"Completion of preoperative systemic chemotherapy with biochemical, metabolic, and/or radiographic response defined as a reduction in the baseline CA 19-9 by > 50% or radiographic response as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 or metabolic response on positron emission tomography (PET)-magnetic resonance imaging (MRI) defined by PET Response Criteria in Solid Tumors (PERCIST) criteria"
NCT04858334,5,"Patient must (1) be planning to receive, (2) be receiving or (3) have received at least three combined months (i.e., 12 weeks) of perioperative (neoadjuvant, adjuvant or a combination of both) systemic, multi-agent chemotherapy. Patients may have had up to 6 months of perioperative systemic therapy as deemed appropriate by their primary treating medical team (patients can have received radiation or chemoradiation in addition to this 6 month course)"
NCT04858334,6,"Patient must be no more than 12 weeks from their most recent treatment (this may be chemotherapy, radiotherapy or surgery)"
NCT04858334,10,"Patient must have undergone at least 3 combined months (i.e., 12 weeks) of perioperative (neoadjuvant, adjuvant or a combination of both) systemic, multi-agent chemotherapy. Patients may have had up to 6 months of perioperative systemic therapy as deemed appropriate by their primary treating medical team (patients can have received radiation or chemoradiation in addition to this 6 months course)"
NCT04858334,15,Patient must be >= 21 days (three weeks) from their last treatment (including chemotherapy radiotherapy or surgery) but =< 84 days (twelve weeks) from their last treatment at the time of Step 1 randomization. Patients who have received neoadjuvant and/or adjuvant radiotherapy are eligible
NCT04858334,18,Patient must not have any history of allergic reactions attributed to compounds of similar chemical or biological composition to olaparib
NCT04858334,20,"Patient must not have any uncontrolled gastrointestinal disorder that would, in the opinion of the investigator, interfere with the ingestion or absorption of olaparib"
NCT04858334,21,"Patient must not be pregnant or breast-feeding due the potential harm to an unborn fetus and possible risk for adverse events in nursing infants with the treatment regimens being used. All patients of childbearing potential must have a blood test or urine study within 14 days prior to Step 1 randomization to rule out pregnancy. A patient of childbearing potential is defined as anyone, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy; or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)"
NCT04858334,22,Patients must not expect to conceive or father children by using accepted and effective method(s) of contraception or by abstaining from sexual intercourse for the duration of their participation in the study and for 6 months after the last dose of protocol treatment for female patients and for 3 months after the last dose of protocol treatment for male patients. Patients must also not donate sperm while on protocol treatment and for 3 months after the last dose of protocol treatment. Patients must also not breast-feed while on protocol treatment and for 1 month after the last dose of protocol treatment
NCT04858334,26,Hemoglobin >= 9.0 g/dL with no blood transfusion in the past 28 days (obtained =< 28 days prior to Step 1 randomization)
NCT04858334,29,Creatinine =< 1.5 institutional ULN OR calculated Cockcroft Gault creatinine clearance > 50 mL/min/1.73 m^2 (obtained =< 28 days prior to Step 1 randomization)
NCT04858334,34,"Concomitant use of known potent CYP3A4/5 inhibitors such as ketoconazole, itraconazole, ritonavir, indinavir, saquinavir, telithromycin, clarithromycin and nelfinavir is prohibited"
NCT04858334,35,"Patients who are being actively treated for an ongoing concurrent malignancy are ineligible, with the exception of those receiving adjuvant hormone therapies and those receiving topical therapies for skin cancers"
NCT04858334,37,"Patient must not be considered a poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease or active, uncontrolled infection. Examples include, but are not limited to, uncontrolled ventricular arrhythmia, recent (within 3 months) myocardial infarction, uncontrolled major seizure disorder, unstable spinal cord compression, superior vena cava syndrome, extensive interstitial bilateral lung disease on high resolution computed tomography (HRCT) scan or any psychiatric disorder that prohibits obtaining informed consent"
NCT04868604,5,"Positive 64Cu-SAR-bisPSMA PET/CT scan, where 64Cu-SAR-bisPSMA uptake (standardized uptake value [SUV] max) of at least 1 known lesion is higher than that of the liver on the 1 hour positron emission tomography (PET)/computed tomography (CT) scan;"
NCT04868604,6,Castrate level of serum/plasma testosterone (<50 ng/dL or <1.7 nmol/L);
NCT04868604,7,Have progressive metastatic castration-resistant prostate cancer (mCRPC) despite prior androgen deprivation therapy and at least either enzalutamide and/or abiraterone (or other such androgen receptor pathway inhibitors). Documented progressive mCRPC will be based on at least 1 of the following criteria:
NCT04868604,10,Progression of bone disease: evaluable disease or new bone lesions(s) by bone scan.
NCT04868604,11,"≥1 metastatic lesion that is present at screening CT, magnetic resonance imaging (MRI), or bone scan imaging obtained ≤28 days prior to enrollment into the study;"
NCT04868604,12,"Participants must have recovered to ≤ Grade 2 from all clinically significant toxicities related to prior therapies (prior chemotherapy, radiation, immunotherapy, etc.);"
NCT04876456,5,"Must have progressed after first-line cisplatin based combination chemotherapy AND demonstrated progression following at least one salvage regimen for advanced germ cell neoplasm and now considered incurable with standard therapies, including further chemotherapy or surgery
* “Failure” of prior therapy is defined as:
** A > 25% increase in the products of the perpendicular diameters of measurable tumor masses during prior therapy which are not amenable to surgical resection
** The presence of new tumors that are not amenable to surgical resection
** An increase in alpha-fetoprotein (AFP) or beta-human chorionic gonadotropin (beta-HCG) (two separate determinations at least one week apart are required if rising tumor markers are the only evidence of failure)
* NOTE: Subjects with clinically growing teratoma (normal declining tumor markers and radiographic or clinical progression) should be considered for surgery"
NCT04876456,7,Subjects with late relapse (> 2 years from previous chemotherapy) not amenable to resection are eligible if they have received first line platinum based chemotherapy and are deemed not amenable to surgical resection (no need for 1 salvage regimen in late relapse patients to be eligible)
NCT04876456,18,Serum creatinine =< 2.0 x ULN or calculated creatinine clearance >= 30 mL/min (>= 0.5 mL/sec) using the Cockcroft-Gault equation (within 10 days prior to registration for protocol therapy)
NCT04876456,22,Male subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapy
NCT04883242,1,"Patients with relapsed or refractory multiple myeloma, with >= 1 prior therapy"
NCT04883242,2,Must have received prior lenalidomide therapy
NCT04883242,6,"Subjects should have resolution of any toxicities from prior therapy to grade =< 1 or baseline prior
to enrollment (with the exception of peripheral neuropathy)"
NCT04883242,8,Prior autologous stem cell transplant is allowed; patients must be >= 6 months post- autologous stem cell transplantation to enroll
NCT04883242,16,"Female patients of childbearing potential and male patients must agree to use 2 effective forms of contraception or continuously abstain from heterosexual intercourse during the period of therapy, and for 6 months after discontinuation of study treatment for females and 3 months after discontinuation of study treatment for males"
NCT04895436,1,"Previously completed venetoclax + anti-CD20 antibody +/- X regimen as a fixed duration first-line (1L) therapy and achieved documented response, defined as complete remission, complete remission with incomplete marrow recovery, partial remission, or nodular partial remission."
NCT04895436,2,More than 24 months (Cohort 1) or 12-24 months (Cohort 2) have elapsed between last dose of venetoclax and disease progression after completion of 1L treatment.
NCT04915508,1,"History of histologically confirmed, clinical localized adenocarcinoma of the prostate treated with radical prostatectomy with definitive intent"
NCT04915508,2,"Presence of any ONE of the following:
* Adverse pathologic features at the time of prostatectomy (positive surgical margin, pathologic T-stage 3-4 disease, pathologic Gleason score 8-10 disease, OR presence of tertiary Gleason grade 5 disease)
* Documentation of rising prostate-specific antigen on at least two consecutive draws, with the magnitude of prostate-specific antigen exceeding 0.03 ng/mL
* Intermediate- or high-risk Decipher genomic classifier score
* Identification of prostate cancer in >= 1 lymph node at the time of prostatectomy (pN+ disease)"
NCT04915508,4,Bone scan OR advanced nuclear imaging study within 120 days prior to enrollment for patients with PSA > 1.0 ng/mL
NCT04919369,4,Patients must have received standard of care chemotherapy and/or immunotherapy. No limits to prior lines of therapy. Prior PD-1 and/or PD-L1 directed therapies are permitted
NCT04919369,5,"Patients with adenocarcinoma and known actionable mutations with FDA-approved treatment options must have received all approved and standard of care treatment options (ie osimertinib for EGFR, alectinib for ALK, etc). Mutational testing is not required for patients with squamous cell non-small cell lung carcinoma"
NCT04919369,11,Serum creatinine =< 1.5 X upper limit of normal (ULN) OR measured or calculated creatinine clearance (glomerular filtration rate [GFR] can also be used in place of creatinine or creatinine clearance [CrCl]) >= 60 mL/min for subject with creatinine levels > 1.5 X institutional ULN
NCT04919369,12,Serum total bilirubin =< 1.5 X ULN OR direct bilirubin =< ULN for subjects with total bilirubin levels > 1.5 ULN. Patients with known Gilbert disease: serum bilirubin =< 3 x ULN
NCT04919369,14,Albumin >= 2.5 mg/dL
NCT04919369,20,"For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods, and agreement to refrain from donating eggs, as defined below:
* Women must remain abstinent or use contraceptive methods with a failure rate of < 1% per year during the treatment period and for 5 months after the final dose of atezolizumab or ATRA. Women must refrain from donating eggs during this same period. 
* A woman is considered to be of childbearing potential if she is postmenarchal, has not reached a postmenopausal state (>= 12 continuous months of amenorrhea with no identified cause other than menopause), and has not undergone surgical sterilization (removal of ovaries and/or uterus).  The definition of childbearing potential may be adapted for alignment with local guidelines or requirements.
* The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient.  Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not adequate methods of contraception."
NCT04919369,21,"For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating sperm, for 5 months from last atezolizumab dose, as defined below
* For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use a condom, and agreement to refrain from donating sperm, as defined below:
** With a female partner of childbearing potential or pregnant female partner, men must remain abstinent or use a condom during the treatment period ATRA to avoid exposing the embryo. Men must refrain from donating sperm during this same period.
* The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not adequate methods of preventing drug exposure."
NCT04960579,4,"Must have relapsed / refractory MM, having received treatment with a proteasome inhibitor, immunomodulatory agent (IMiD), and anti-CD38 therapy."
NCT04960579,6,Must have a negative serum pregnancy test at Screening and a negative urine pregnancy test within 3 days prior to initiating the lymphodepletion therapy regimen (females of childbearing potential).
NCT04963153,2,"Patients who had disease progression during or following treatment with at least one platinum-containing regimen (e.g., gemcitabine and cisplatin [GC], methotrexate, vinblastine, doxorubicin and cisplatin [MVAC], carboplatin and gemcitabine [Carbo-Gem]) and an immune checkpoint inhibitor (PD-1/ PD-L1 inhibitor including but not limited to: atezolizumab, pembrolizumab, durvalumab, avelumab, and nivolumab)
* Received a first-line platinum-containing regimen in the metastatic setting or for inoperable locally advanced disease 
* Or received neo/adjuvant platinum-containing therapy for localized muscle-invasive UC, with recurrence/progression =< 12 months following completion of therapy 
* Patients who received immune checkpoint inhibitor therapy in the neoadjuvant/adjuvant setting and had recurrent or progressive disease either during therapy or within 12 months of therapy completion are eligible. This criterion does not apply if the checkpoint inhibitor is contraindicated"
NCT04963153,3,Patients with metastatic urothelial carcinoma who are cisplatin-ineligible and progressed on upfront immune checkpoint inhibitor; or ineligible/refused immune checkpoint inhibitor therapy will be eligible for this trial
NCT04963153,4,Patient who received prior antibody drug conjugate such as sacituzumab govitecan are allowed
NCT04963153,5,"Patients must have measurable disease, as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1. Previously irradiated lesions cannot be counted as target lesions unless there has been demonstrated progression in the lesion since radiotherapy and no other lesions are available for selection as target lesions"
NCT04963153,7,"Age >= 18 years, for ability to comply with protocol
* Because no dosing or adverse event data are currently available on the use of erdafitinib in combination with enfortumab vedotin in patients < 18 years of age, children are excluded from this study"
NCT04963153,12,Measured or calculated creatine clearance (CrCl) >= 30 ml/min (glomerular filtration rate [GFR] can also be used in place of creatinine CrCl) (within 14 days prior to beginning trial treatment)
NCT04963153,19,"Patients with a history of prostate cancer (T2NXMX or lower with Gleason score =< 7) treated with definitive intent (surgically or with radiation therapy) at least 1 year prior to study entry are eligible, provided that the subject is considered prostate cancer-free and the following criteria are met: 
* Patients who have undergone radical prostatectomy must have undetectable prostate specific antigen (PSA) for > 1 year and at screening
* Patients who have had radiation must have a PSA doubling time > 1 year (based on at least 3 values determined >1 month apart) and a total PSA value that does not meet Phoenix criteria for biochemical recurrence (i.e., < 2.0 ng/mL above nadir)
* Patients with untreated low-risk prostate cancer (Gleason score =< 6) on active surveillance with PSA doubling time >1 year (based on at least 3 values determined > 1 month apart) are also eligible"
NCT04963153,21,"The effects of erdafitinib and enfortumab vedotin on the developing human fetus are unknown. For this reason and because FGFR inhibitors and humanized antibody-drug conjugate (ADC) agents are known to be teratogenic, women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and 3 months after completion of erdafitinib and enfortumab vedotin administration. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 5 months after completion of erdafitinib and enfortumab vedotin administration"
NCT04966481,1,"Histologically or cytologically confirmed recurrent or metastatic (RM)-HNSCC that is HPV-unrelated disease; defined as squamous cell carcinoma (SCC) of the oral cavity, larynx, or hypopharynx and p16 negative SCC of the oropharynx or p16 negative non-cutaneous SCC unknown primary of the neck."
NCT04966481,3,"Measurable disease defined as lesions that can be accurately measured in at least one dimension (longest diameter to be recorded) as >= 10 mm with CT scan, as >= 20 mm by chest x-ray, or >= 10 mm with calipers by clinical exam, per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1."
NCT04966481,4,Disease progression on a PD-1/L1 inhibitor-containing regimen (given as monotherapy or in combination with other therapy).
NCT04966481,5,Received no more than three lines of prior therapy for RM-HNSCC.
NCT04966481,12,"Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) / alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 5 x IULN (for cases involving liver metastases, AST/ALT =< 10 x IULN)."
NCT04966481,13,Serum creatinine < 3 x IULN or creatinine clearance >= 30 mL/min by Cockcroft-Gault.
NCT04966481,14,"The effects of palbociclib and cetuximab on the developing human fetus are unknown. For this reason and because CDK 4/6 inhibitors are known to be teratogenic, women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control, abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of the study, and 3 months after completion of the study."
NCT04971499,2,"Has unresectable Stage III or Stage IV melanoma, per AJCC 8th Edition Staging Criteria, not amenable to local therapy."
NCT04971499,4,Male participants must agree to use a reliable method of contraception during the treatment period and for at least 120 days after the last dose of study drug and must refrain from donating sperm during this period.
NCT04971499,5,"Female participants must not be pregnant or breast feeding and meet at least one of the following conditions:
* Not a woman of childbearing potential (WOCBP)
* A WOCBP must agree to use a reliable method of contraception during the treatment period and for at least 120 days after the last dose of study treatment."
NCT04971499,6,Participants must have received an anti-PD-1/PD-L1 monoclonal antibody (mAb) as part of their most recent line of therapy prior to enrollment in the study.
NCT04971499,7,"Participants must have progressed on or after treatment with an anti-PD-1/PD-L1 mAb administered either as monotherapy or in combination with other checkpoint inhibitors or other therapies in their most recent line of therapy. PD 1 treatment progression is defined by meeting all of the following criteria:
* Has received at least 8 weeks of an anti-PD-1/PD-L1 mAb.
* Has demonstrated progression after anti-PD-1/PD-L1 mAb therapy as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. The initial evidence of progressive disease (PD) is to be confirmed by a second assessment no less than 4 weeks from the date of the first documented PD, in the absence of rapid clinical progression.
* Progressive disease has been documented within 6 months from the last dose of anti-PD-1/L1 mAb.
** Progressive disease must be determined according to Immune-Modified Response Evaluation Criteria in Solid Tumors (iRECIST).
** This determination is made by the investigator. Once PD is confirmed, the initial date of PD documentation will be considered the date of disease progression.
* Patients who progress while receiving or within 6 months of receiving the last dose of anti-PD-1/L1 mAb in the neoadjuvant or adjuvant setting will be included. Inclusion of patients who progress within 6 months of stopping neoadjuvant or adjuvant anti-PD-1/L1 mAb will be capped at 20% of the total study population. Inclusion of patients who progress while still receiving neoadjuvant or adjuvant anti-PD-1/L1 mAB will not be capped."
NCT04971499,10,"Have available archival tumor tissue sample or newly obtained core or excisional biopsy of a tumor lesion. Formalin-fixed, paraffin embedded (FFPE) tissue blocks are preferred to slides.
* Newly obtained biopsies are preferred to archived tissue, but archived sample can be used at baseline provided that the patient has only had anti-PD-1/L1 based regimen since obtaining the sample.
* Biopsies may be taken from any amenable lesion, but it is preferable to use the same lesion throughout. 
* Biopsy may be taken from previously irradiated lesions only if they have progressed since radiation therapy.
* Patient may still be eligible for study if tumor is not amenable to safe biopsy or biopsy is judged by patient or treating physician to not be in their best interest."
NCT04971499,15,"Creatinine =< 1.5 x ULN (upper limit of normal) OR measured or calculated creatinine clearance (CrCl) (glomerular filtration rate [GFR] can be used in place of CrCl) >= 45 mL/min for participant with creatinine levels > 1.5 x institutional ULN (within 7 days prior to the start of study treatment).
* Creatinine clearance (CrCl) should be calculated per institutional standard."
NCT04971499,20,"Prior adverse events from anticancer therapy must be resolved to =< grade 1, with the exception of alopecia or endocrinopathies, which may be on replacement therapy. Prednisone equivalent of =< 10 mg is allowed."
NCT04974671,6,"The most recent systemic therapy must be an ICI-containing regimen, delivered for at least 3 months prior to development of oligoprogressive lesions, with the last dose received within 3 months of trial enrollment."
NCT04974671,7,"Oligoprogression – defined as documented progression in up to 5 individual lesions with no previous local therapy to those sites using one of the following criteria:
* Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
** At least a 20% increase in the sum of diameters of target lesions (long axis for non-nodal lesions, short axis for nodal lesions), using the previous imaging as a baseline
** The sum of all diameters must demonstrate an absolute increase of at least 5 mm
** The appearance of at least one new unequivocal lesion
* Positron Emission Tomography Response Criteria in Solid Tumors (PERCIST)
** Peak standardized uptake (SUVpeak), normalized to lean body mass (SUL) increase by at least 30% and increase by at least 0.8 SUL of the target lesion
** Development of at least one new lesion
** Increase in target lesion size by 30%
** Unequivocal progression of nontarget lesions"
NCT04974671,14,"Serum creatinine =< 1.5 X upper limit of normal (ULN) OR measured or calculated creatinine clearance (glomerular filtration rate [GFR] can also be used in place of creatinine or creatinine clearance [CrCl]) >= 30 mL/min for subject with creatinine levels > 1.5 X institutional ULN (should be performed within 28 days of protocol treatment)
* Creatinine clearance should be calculated per institutional standard
* IF SBRT will be delivered to a lesion in or abutting the kidney"
NCT04974671,20,"Female subjects of childbearing must use an effective form of birth control during this study. Acceptable and highly effective birth control methods include intra-uterine hormone releasing system as well as other methods of birth control including consistent use of an approved oral contraceptive (birth control pill), an implantable contraceptive, an injectable contraceptive, a double-barrier method, or true abstinence. Oral, implantable, or injectable contraceptives are only considered effective if used properly and started at least 30 days prior to the screening visit and continue for 120 days after last dose of study drug. Male subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 6 months after the last dose of study therapy."
NCT04977024,3,"Allogeneic or autologous hematopoietic cell transplant (HCT), cellular therapy (chimeric antigen receptor [CAR] T-cell) recipients who are at >= 3 months of infusion date of respective regimen"
NCT04977024,9,Creatinine < 1.5 X ULN (to be performed within 30 days prior to day 0 of protocol therapy unless otherwise stated)
NCT04977024,11,Women of childbearing potential (WOCBP): negative urine or serum pregnancy test (to be performed within 30 days prior to day 0 of protocol therapy unless otherwise stated). If the urine pregnancy test is inconclusive a serum pregnancy test will be required
NCT05002816,4,"Prior line of therapy must include immunomodulatory imide drug (iMID), proteasome inhibitor, and anti-CD38 monoclonal antibody. Prior elotuzumab is allowed"
NCT05002816,8,Total bilirubin =< 1.5 X upper limit of normal (ULN) (isolated bilirubin >= 1.5 x ULN is acceptable if bilirubin is fractionated and direct bilirubin < 35%)
NCT05002816,10,"Estimated glomerular filtration rate (eGFR) >= 40 mL/min/ 1.73 m^2
* As calculated by Modified Diet in Renal Disease (MDRD) formula"
NCT05002816,13,"Female participants: contraceptive use should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies:
* Is not a woman of childbearing potential (WOCBP) OR
* Is a WOCBP and using a contraceptive method that is highly effective (with a failure rate of < 1% per year), preferably with low user dependency, during the intervention period and for at least 4 months after the last dose of study intervention and agrees not to donate eggs (ova, oocytes) for the purpose of reproduction during this period. The investigator should evaluate the effectiveness of the contraceptive method in relationship to the first dose of study intervention.
A WOCBP must have a negative highly sensitive serum pregnancy test (as required by local regulations) within 72 hours before the first dose of study intervention.
The investigator is responsible for review of medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a woman with a nearly undetected pregnancy.
Nonchildbearing potential is defined as follows (by other than medical reasons):
* >= 45 years of age and has not had menses for > 1 year
* Patients who have been amenorrhoeic for < 2 years without history of a hysterectomy and oophorectomy must have a follicle stimulating hormone value in the postmenopausal range upon screening evaluation
* Post-hysterectomy, post-bilateral oophorectomy, or post-tubal ligation. Documented hysterectomy or oophorectomy must be confirmed with medical records of the actual procedure or confirmed by an ultrasound. Tubal ligation must be confirmed with medical records of the actual procedure"
NCT05002816,14,"Male participants: contraceptive use should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. Male participants are eligible to participate if they agree to the following during the intervention period and for 6 months after the last dose of study treatment to allow for clearance of any altered sperm:
* Refrain from donating sperm 
PLUS either:
* Be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent.
OR
* Must agree to use contraception/barrier as detailed below:
** Agree to use a male condom, even if they have undergone a successful vasectomy, and female partner to use an additional highly effective contraceptive method with a failure rate of < 1% per year as when having sexual intercourse with a woman of childbearing potential (including pregnant females)"
